

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Study No.: 113165 (EARLY-CLINRES-004)
Title: A study to evaluate the safety and immunogenicity of a booster dose of GSK Biologicals' HIV candidate vaccine (732461) after administration of chloroquine in healthy adults.
Rationale: The aim of the study was to assess whether chloroquine had an effect on the CD8+ T cell response to a booster dose of HIV vaccine in subjects recruited amongst CD4+T cell responders who received 2 primary HIV doses in the PRO-HIV-005 (108706) study. The study also aimed at evaluating the safety of a booster dose of HIV vaccine.
<i>Nivaquine®</i> (chloroquine) from Aventis Pasteur (formerly Sanofi Pasteur)
Phase: II
Study Period: 07 December 2009 - 04 October 2010
Study Design: Open-label, randomised study with 2 parallel treatment groups.
Centres: 1 centre in Belgium
Indication: Immunisation against HIV in healthy adults.
Treatment: The treatment groups were as follows: <ul style="list-style-type: none"> • HIV-CQ Group: Subjects received a single dose of chloroquine, 2 days before a booster dose of the HIV vaccine. • HIV Group: Subjects received a booster dose of the HIV vaccine. The HIV booster dose was given intramuscularly in the deltoid muscle of (preferably) the non-dominant arm.
Objectives: <ul style="list-style-type: none"> • To evaluate the effect of chloroquine on a specific CD8+ T-cell response to the HIV candidate vaccine at Day 14. • To evaluate the safety of a booster dose of the HIV investigational vaccine.
Primary Outcome/Efficacy Variables: <i>Immunogenicity</i> <ul style="list-style-type: none"> • Cellular immune response to components of the study vaccine at Day 14. <u>Criteria for assessment:</u> <ul style="list-style-type: none"> – CD8+ T-cell responder rate identified as the number of subjects with frequencies of CD8+ T-cells expressing at least 1 cytokine among Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and Interferon gamma (IFN-γ) equal or above the cut-off to at least 1, 2, 3 antigens and to all 4 antigens at Day 14, as determined by Intracellular Cytokine Staining (ICS). <i>Safety</i> <ul style="list-style-type: none"> • Occurrence, intensity and relationship to vaccination of solicited local and general symptoms during a 7-day (Day 0 to Day 6) follow up period after vaccination. • Occurrence, intensity and relationship to vaccination of unsolicited adverse events (AEs) until Day 29 Post-Vaccination. <u>Criteria for assessment:</u> <ul style="list-style-type: none"> – Occurrence, intensity and relationship to vaccination of unsolicited AEs during the 32 days (Day -2 to Day 29) follow-up period after chloroquine administration for HIVCQ Group or the 30 days (Day 0 to Day 29) follow-up period after vaccination for HIV Group. • Occurrence and relationship to vaccination of serious adverse event during the whole study period. • Occurrence and relationship to vaccination of adverse event of specific interest, including Immune-Mediated Disorders (IMD) during the whole study period. • Haematological and biochemical levels at Days 0, 7, 30 and 180 (visits 1, 2, 4 and 5) in all subjects.
Secondary Outcome/Efficacy Variable: <i>Immunogenicity</i> <ul style="list-style-type: none"> • Cellular and humoral immune response to components of the candidate vaccines at Days 0, 7, 14, 30 and 180 in all subjects. <u>Criteria for assessment:</u> <ul style="list-style-type: none"> – Frequency of p17, p24, Negative Regulatory Factor (Nef) and Reverse Transcriptase (RT)-specific CD8+ T cells expressing IL-2 and/or IFN-γ and/or TNF-α, as determined by Intracellular Cytokine Staining (ICS). – Frequency of p17, p24, Nef and RT-specific CD8+ T cells expressing at least one cytokine/marker among IL-2,

<p>TNFα, IFNγ equal or above the cut-off value.</p> <ul style="list-style-type: none"> – Cytokine/marker co-expression profile of the antigen-specific CD8$^{+}$ T cells: Frequency of p17, p24, Nef and RT-specific CD8$^{+}$ T cells expressing IL-2 and/or TNF-α and/or IFN- γ and/or CD40L, as determined by ICS and analysed by FlowJo software or equivalent. – Frequency of p17, p24, Nef and RT-specific CD4$^{+}$ T cells expressing IL-2 and/or TNF-α and/or IFN- γ and/or CD40-L, as determined by ICS. – Frequency of p17, p24, Nef and RT-specific CD4$^{+}$ T cells expressing at least 2 cytokines including IL-2 equal or above the cut-off value. – Cytokine/marker co-expression profile of the antigen-specific CD4$^{+}$ T cells: Frequency of p17, p24, Nef and RT-specific CD4$^{+}$ T cells expressing CD40L and/or IL-2 and/or TNF-α and/or IFN- γ, as determined by ICS and analysed by FlowJo software or equivalent. – Antibody titres to p17, p24, Nef, RT and F4co (fusion protein) as measured by Enzyme-Linked Immunosorbent Assay (ELISA).
<p>Statistical Methods:</p> <p>Population</p> <p>The analyses were performed on the Total Vaccinated Cohort (TVC) and the According-To-Protocol (ATP) cohort for immunogenicity.</p> <ul style="list-style-type: none"> • The Total Vaccinated Cohort included all vaccinated subjects. • The According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures defined in the protocol, with no elimination criteria during the study), for whom data concerning immunogenicity outcome measures were available. <p><i>Analysis of Immunogenicity:</i></p> <p>The analyses of immunogenicity were performed on the ATP cohort for immunogenicity.</p> <p>The difference between groups in term of percentage of CD8$^{+}$ T cell responders with T cells expressing at least one cytokine among IL-2, IFNγ and TNFα equal or above the cut-off to at least 1, 2, 3 antigens and to all 4 antigens was tabulated with standardised asymptotic 95 % confidence interval (CI).</p> <p>For each treatment group, at each blood sampling time point for which results were available, descriptive statistics of the following parameters were tabulated:</p> <p>For the CD8$^{+}$ T-cell response:</p> <ul style="list-style-type: none"> • The responder rate was defined as the number of CD8$^{+}$ T-cell responders identified with frequencies of CD8$^{+}$ T-cells expressing at least 1 cytokine among IL-2, TNF-α and IFN-γ equal or above the cut-off to at least 1, 2, 3 antigens and to all 4 antigens and to each individual antigen. The cut-off values for the specific CD8$^{+}$ T-cell responses were obtained based on the pre-booster responses to the different antigens/ the peptide pool spanning the complete recombinant F4 antigen. • The magnitude was defined as the frequency of p17, p24, Nef, RT and F4co*-specific CD8$^{+}$ T-cells expressing at least 1 cytokine among IL-2, TNF-α and IFN-γ. • The cytokine/marker co-expression profile was defined as the frequency of p17, p24, Nef, RT and F4co*-specific CD8$^{+}$ T-cells expressing IL-2 and/or TNF-α and/or IFN-γ and/or CD40L, as determined by ICS and analysed by FlowJo software or equivalent. <p>For CD4$^{+}$ T-cell response:</p> <ul style="list-style-type: none"> • The responder rate was defined as the number of CD4$^{+}$ T-cell responders identified with the frequency CD4$^{+}$ T-cells expressing at least 2 cytokines including IL-2 equal or above the cut-off value to at least 1, 2, 3 and to all 4 antigens and to each individual antigen. The cut-off values for the specific CD4$^{+}$ T-cell responses were determined as 300 (positive CD4$^{+}$ T-cells per million CD4$^{+}$ T-cells) in the PRO-HIV-005 study. • The magnitude was defined as the frequency of p17, p24, Nef, RT and F4co*-specific CD4$^{+}$ T-cells expressing at least 2 cytokines including IL-2. • The cytokine/marker co-expression profile was defined as the frequency of p17, p24, Nef, RT and F4co*-specific CD4$^{+}$ T-cells expressing CD40L and/or IL-2 and/or TNF-α and/or IFN-γ, as determined by ICS and analysed by FlowJo software or equivalent. <p>* The frequency of CD4$^{+}$/CD8$^{+}$ T-cells expressing cytokines in response to the fusion protein F4co was determined by 2 different methods: by stimulating with a peptide pool spanning the F4 antigen, or by adding the individual frequencies of the CD4$^{+}$/CD8$^{+}$ T-cell response to each of the 4 individual antigens (p17, p24, Nef and RT).</p> <p>For humoral immune response, the following parameters were tabulated by vaccine groups for each antigen (p17, p24, Nef, RT and F4co) at each blood sampling time point for which antibody concentrations were available:</p>

- GMCs with 95% confidence intervals (CIs).
- Seropositivity rates with exact 95% CIs.

Analysis of Safety

The analyses of safety were based on the Total Vaccinated Cohort.

The percentages of subjects reporting each solicited local and general symptom during the 7-day (Days 0 - 6) follow-up period after vaccination, were tabulated with exact 95% CI for each group. The same tabulation was performed for any grade 3 symptoms and for general symptoms assessed by the investigator as causally related to vaccination.

The percentage of subjects with at least one report of unsolicited adverse event (AE) classified by Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms and reported during the 32 days (Days -2-29) follow-up period after chloroquine administration for HIV-CQ Group or 30 days (Days 0-29) follow-up period after vaccination for HIV Group was tabulated. The same tabulation was performed for grade 3 unsolicited AEs and for AEs assessed by the investigator as causally related to vaccination. The percentage of subjects with at least one report of AEs of specific interest including IMD during the entire study period was tabulated.

SAEs were collected and summarized by MedDRA Preferred Terms through the entire study period.

For all clinical laboratory parameters, the frequency distribution of values below, within and above normal range was tabulated per group, at each time point.

Study Population: Healthy male or female subjects between, and including, 18 and 52 years at the time of the first vaccination, who had participated and completed the PRO-HIV-005 (108706) study were enrolled in the study. Female subjects of childbearing potential had to practice adequate contraception for 30 days prior to vaccination, to have a negative pregnancy test and were to continue such precautions for 2 months after vaccination. Subjects should not have any previous administration of vaccine components nor received any previous vaccination against HIV. Written informed consent was obtained from the subjects prior to any study procedure.

Number of subjects	HIV-CQ Group	HIV Group
Planned, N	22	22
Randomised, N (Total Vaccinated Cohort)	13	15
Completed, n (%)	13 (100)	15 (100)
Total Number Subjects Withdrawn, n (%)	0 (0.0)	0 (0.0)
Withdrawn due to Adverse Events, n (%)	0 (0.0)	0 (0.0)
Withdrawn due to Lack of Efficacy, n (%)	Not applicable	Not applicable
Withdrawn for other reasons, n (%)	0 (0.0)	0 (0.0)
Demographics	HIV-CQ Group	HIV Group
N (Total Vaccinated Cohort)	13	15
Females:Males	7:6	10:5
Mean Age, years (SD)	25.1 (5.33)	24.3 (3.73)
White - Caucasian / European heritage, n (%)	13 (100)	13 (86.7)

Primary Efficacy results: Difference between groups in percentage of responders to at least 1, 2, 3 and all 4 antigens: CD8⁺ T cells expressing at least 1 cytokine amongst IL-2, TNF α and IFN γ (ATP cohort for immunogenicity)

								Difference in percentage (HIV-CQ minus HIV)		
		HIV-CQ Group			HIV Group			95% CI		
Number of antigens	Timing	N	n	%	N	n	%	%	LL	UL
At least 1 antigen	PIII(D14)	13	1	7.69	13	3	23.08	-15.4	-45.1	15.39
At least 2 antigens	PIII(D14)	13	0	0.00	13	0	0.00	0.00	-23.5	23.51
At least 3 antigens	PIII(D14)	13	0	0.00	13	0	0.00	0.00	-23.5	23.51
All 4 antigens	PIII(D14)	13	0	0.00	13	0	0.00	0.00	-23.5	23.51

N=number of subject with available results

n/%=number/percentage of responders

95%CI=standardised asymptotic 95% confidence interval, LL=lower limit, UL=upper limit

PIII(D14)=Day 14 Post Dose 3, i.e. 14 days after the booster dose

Primary Efficacy Results: Frequency (responder rate) of CD8⁺ T-cells expressing at least 1 cytokine among IL-2, IFN γ and TNF α : Number and percentage of responders to at least 1, 2, 3 and all 4 antigens (ATP cohort for immunogenicity)

							95% CI	
Group	Timing	Number of antigens	N	n	%	LL %	UL	
HIV-QC	PRE	At least 1 antigen	13	3	23.1	5.0	53.8	

		At least 2 antigens	13	0	0.0	0.0	24.7
		At least 3 antigens	13	0	0.0	0.0	24.7
		All 4 antigens	13	0	0.0	0.0	24.7
	PIII(D7)	At least 1 antigen	12	1	8.3	0.2	38.5
		At least 2 antigens	12	0	0.0	0.0	26.5
		At least 3 antigens	12	0	0.0	0.0	26.5
		All 4 antigens	12	0	0.0	0.0	26.5
	PIII(D14)*	At least 1 antigen	13	1	7.7	0.2	36.0
		At least 2 antigens	13	0	0.0	0.0	24.7
		At least 3 antigens	13	0	0.0	0.0	24.7
		All 4 antigens	13	0	0.0	0.0	24.7
	PIII(D30)	At least 1 antigen	11	0	0.0	0.0	28.5
		At least 2 antigens	11	0	0.0	0.0	28.5
		At least 3 antigens	11	0	0.0	0.0	28.5
		All 4 antigens	11	0	0.0	0.0	28.5
	PIII(D180)	At least 1 antigen	13	1	7.7	0.2	36.0
		At least 2 antigens	13	0	0.0	0.0	24.7
		At least 3 antigens	13	0	0.0	0.0	24.7
		All 4 antigens	13	0	0.0	0.0	24.7
HIV	PRE	At least 1 antigen	14	3	21.4	4.7	50.8
		At least 2 antigens	14	1	7.1	0.2	33.9
		At least 3 antigens	14	0	0.0	0.0	23.2
		All 4 antigens	14	0	0.0	0.0	23.2
	PIII(D7)	At least 1 antigen	13	3	23.1	5.0	53.8
		At least 2 antigens	13	1	7.7	0.2	36.0
		At least 3 antigens	13	0	0.0	0.0	24.7
		All 4 antigens	13	0	0.0	0.0	24.7
	PIII(D14)*	At least 1 antigen	13	3	23.1	5.0	53.8
		At least 2 antigens	13	0	0.0	0.0	24.7
		At least 3 antigens	13	0	0.0	0.0	24.7
		All 4 antigens	13	0	0.0	0.0	24.7
	PIII(D30)	At least 1 antigen	13	1	7.7	0.2	36.0
		At least 2 antigens	13	0	0.0	0.0	24.7
		At least 3 antigens	13	0	0.0	0.0	24.7
		All 4 antigens	13	0	0.0	0.0	24.7
	PIII(D180)	At least 1 antigen	14	0	0.0	0.0	23.2
		At least 2 antigens	14	0	0.0	0.0	23.2
		At least 3 antigens	14	0	0.0	0.0	23.2
		All 4 antigens	14	0	0.0	0.0	23.2

N = number of subjects with available results to all 4 antigens

n/% = number/percentage of subjects in the specified category

95% CI = 95% CI confidence interval ; LL = Lower Limit, UL = Upper Limit

PRE = Pre Dose 3, i.e. Pre-Booster dose

PIII(D7) = Day 7 Post Dose 3

PIII(D14) = Day 14 Post Dose 3

PIII(D30) = Day 30 Post Dose 3

PIII(D180) = Day 180 Post Dose 3

*Primary outcome variable

Primary Efficacy Results: Incidence of solicited local symptoms reported during the 7-day (Days 0-6) post-vaccination period (Total vaccinated cohort)

		HIV-CQ Group					HIV Group				
				95 % CI						95 % CI	
Symptom	Type	N	n	%	LL	UL	N	n	%	LL	UL
Pain	Any	13	13	100	75.3	100	15	14	93.3	68.1	99.8
	Grade 3	13	1	7.7	0.2	36.0	15	2	13.3	1.7	40.5

Redness	Any	13	3	23.1	5.0	53.8	15	6	40.0	16.3	67.7
	>50 mm	13	0	0.0	0.0	24.7	15	1	6.7	0.2	31.9
Swelling	Any	13	3	23.1	5.0	53.8	15	5	33.3	11.8	61.6
	>50 mm	13	0	0.0	0.0	24.7	15	2	13.3	1.7	40.5

N= number of subjects with the documented dose

n/%= number/percentage of subjects reporting the symptom at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

Any = incidence of a particular symptom regardless of intensity grade

Grade 3: pain that prevented normal activity

Primary Efficacy Results: Incidence of solicited general symptoms reported during the 7-day (Days 0-6) post-vaccination period (Total vaccinated cohort)

		HIV-CQ Group					HIV Group				
		95 % CI					95 % CI				
Symptom	Type	N	n	%	LL	UL	N	n	%	LL	UL
Fatigue	Any	13	9	69.2	38.6	90.9	15	14	93.3	68.1	99.8
	Grade 3	13	3	23.1	5.0	53.8	15	3	20.0	4.3	48.1
	Related	13	9	69.2	38.6	90.9	15	11	73.3	44.9	92.2
Gastro-intestinal	Any	13	6	46.2	19.2	74.9	15	5	33.3	11.8	61.6
	Grade 3	13	1	7.7	0.2	36.0	15	0	0.0	0.0	21.8
	Related	13	4	30.8	9.1	61.4	15	3	20.0	4.3	48.1
Headache	Any	13	9	69.2	38.6	90.9	15	13	86.7	59.5	98.3
	Grade 3	13	3	23.1	5.0	53.8	15	0	0.0	0.0	21.8
	Related	13	8	61.5	31.6	86.1	15	10	66.7	38.4	88.2
Temperature (Orally)	> 37.5°C	13	8	61.5	31.6	86.1	15	10	66.7	38.4	88.2
	>39°C	13	0	0.0	0.0	24.7	15	1	6.7	0.2	31.9
	Related	13	7	53.8	25.1	80.8	15	9	60.0	32.3	83.7

N= number of subjects with the documented dose

n/%= number/percentage of subjects reporting the symptom at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

Any = incidence of a particular symptom regardless of intensity grade and relationship

Grade 3:= symptom that prevented normal activity

Related = symptom assessed by the investigator as causally related to the vaccination

Primary Efficacy Results: Percentage of subjects reporting the occurrence of adverse event of specific interest, including Immune-Mediated Disorders (IMDs) during the whole study period (Total vaccinated cohort)

	HIV-CQ Group N = 13	HIV Group N = 15
Subjects with any AE of specific interest, including IMDs, n (%)	0 (0.0)	0 (0.0)

Primary Efficacy Results: Distribution of haematology and biochemistry parameters with respect to normal laboratory ranges (Total vaccinated cohort)

		HIV-CQ Group								HIV Group							
		Unknown				Below				Within				Above			
Laboratory parameter	Timin g	N	n	%	n	%	n	%	n	%	N	n	%	n	%	n	%
Alanine Aminotransferase	D0	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100
	D7	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100
	D30	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100
	D180	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100
Aspartate Aminotransferase	D0	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100
	D7	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100
	D30	13	0	0.0	0	0.0	12	92.3	1	7.7	15	0	0.0	0	0.0	15	100
	D180	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100
Basophils	D0	13	0	0.0	3	23.1	10	76.9	0	0.0	15	0	0.0	4	26.7	11	73.3
	D7	13	0	0.0	3	23.1	10	76.9	0	0.0	15	0	0.0	1	6.7	14	93.3
	D30	13	1	7.7	2	15.4	9	69.2	1	7.7	15	0	0.0	2	13.3	12	80.0
	D180	13	0	0.0	1	7.7	12	92.3	0	0.0	15	0	0.0	2	13.3	13	86.7
Creatinine	D0	13	0	0.0	0	0.0	12	92.3	1	7.7	15	0	0.0	0	0.0	14	93.3

	D7	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D30	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D180	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
Eosinophils	D0	13	0	0.0	1	7.7	12	92.3	0	0.0	15	0	0.0	1	6.7	14	93.3	0	0.0
	D7	13	0	0.0	1	7.7	11	84.6	1	7.7	15	0	0.0	1	6.7	12	80.0	2	13.3
	D30	13	1	7.7	0	0.0	11	84.6	1	7.7	15	0	0.0	0	0.0	15	100	0	0.0
	D180	13	0	0.0	1	7.7	11	84.6	1	7.7	15	0	0.0	0	0.0	14	93.3	1	6.7
Haematocrit	D0	13	0	0.0	1	7.7	12	92.3	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D7	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D30	13	1	7.7	0	0.0	12	92.3	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D180	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
Haemoglobin	D0	13	0	0.0	0	0.0	12	92.3	1	7.7	15	0	0.0	0	0.0	15	100	0	0.0
	D7	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D30	13	1	7.7	0	0.0	12	92.3	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D180	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
Lymphocytes	D0	13	0	0.0	1	7.7	12	92.3	0	0.0	15	0	0.0	3	20.0	12	80.0	0	0.0
	D7	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D30	13	1	7.7	1	7.7	11	84.6	0	0.0	15	0	0.0	1	6.7	14	93.3	0	0.0
	D180	13	0	0.0	1	7.7	11	84.6	1	7.7	15	0	0.0	3	20.0	12	80.0	0	0.0
Monocytes	D0	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	14	93.3	1	6.7
	D7	13	0	0.0	0	0.0	11	84.6	2	15.4	15	0	0.0	0	0.0	15	100	0	0.0
	D30	13	1	7.7	0	0.0	12	92.3	0	0.0	15	0	0.0	0	0.0	14	93.3	1	6.7
	D180	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	14	93.3	1	6.7
Neutrophils	D0	13	0	0.0	2	15.4	11	84.6	0	0.0	15	0	0.0	0	0.0	13	86.7	2	13.3
	D7	13	0	0.0	2	15.4	10	76.9	1	7.7	15	0	0.0	1	6.7	14	93.3	0	0.0
	D30	13	1	7.7	3	23.1	9	69.2	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D180	13	0	0.0	2	15.4	10	76.9	1	7.7	15	0	0.0	1	6.7	14	93.3	0	0.0
Platelets	D0	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	14	93.3	1	6.7
	D7	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	14	93.3	1	6.7
	D30	13	1	7.7	0	0.0	12	92.3	0	0.0	15	0	0.0	0	0.0	14	93.3	1	6.7
	D180	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	14	93.3	1	6.7
Red Blood Cells	D0	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D7	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D30	13	1	7.7	0	0.0	12	92.3	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D180	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
Urea	D0	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D7	13	0	0.0	0	0.0	12	92.3	1	7.7	15	0	0.0	0	0.0	15	100	0	0.0
	D30	13	0	0.0	1	7.7	12	92.3	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D180	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
White Blood Cells	D0	13	0	0.0	0	0.0	13	100	0	0.0	15	0	0.0	0	0.0	13	86.7	2	13.3
	D7	13	0	0.0	0	0.0	12	92.3	1	7.7	15	0	0.0	0	0.0	15	100	0	0.0
	D30	13	1	7.7	1	7.7	11	84.6	0	0.0	15	0	0.0	0	0.0	15	100	0	0.0
	D180	13	0	0.0	0	0.0	12	92.3	1	7.7	15	0	0.0	0	0.0	15	100	0	0.0

Unknown = Laboratory value unknown

N = total number of subjects with available results

n(%) = number(percentage) of subjects in the appropriate category

Primary Efficacy Results: For unsolicited AEs and SAEs please refer to the safety section of the document.

Secondary Outcome Variable(s): Frequency (magnitude) of CD8⁺ T-cells expressing at least 1 cytokine among IL-2, IFN- γ and TNF- α : Descriptive statistics (ATP cohort for immunogenicity)

Stimulating Ag	Group	Activity	N	Mean	SD	Median
RT	HIV-CQ	PRE	13	120.69	111.27	79.00
		PIII(D7)	12	246.00	420.41	127.50
		PIII(D14)	13	126.31	94.03	94.00
		PIII(D30)	11	71.27	42.94	57.00
		PIII(D180)	13	37.23	36.59	14.00
	HIV	PRE	14	151.71	153.53	89.00

		PIII(D7)	13	185.62	200.27	137.00
		PIII(D14)	13	112.46	85.13	102.00
		PIII(D30)	13	78.62	54.43	85.00
		PIII(D180)	14	59.21	38.23	48.50
Nef	HIV-CQ	PRE	13	98.00	77.74	75.00
		PIII(D7)	12	94.58	87.86	63.50
		PIII(D14)	13	118.38	71.85	123.00
		PIII(D30)	11	82.73	54.00	61.00
		PIII(D180)	13	65.15	91.74	39.00
	HIV	PRE	14	119.71	125.18	71.00
		PIII(D7)	13	90.38	60.39	84.00
		PIII(D14)	13	86.69	45.01	99.00
		PIII(D30)	13	114.08	74.77	116.00
		PIII(D180)	14	100.21	78.17	66.00
p17	HIV-CQ	PRE	13	111.85	80.86	104.00
		PIII(D7)	12	93.67	52.93	109.50
		PIII(D14)	13	114.08	89.47	124.00
		PIII(D30)	11	47.36	46.74	18.00
		PIII(D180)	13	84.38	92.90	55.00
	HIV	PRE	14	95.86	70.28	76.00
		PIII(D7)	13	306.00	819.59	88.00
		PIII(D14)	13	177.92	257.37	84.00
		PIII(D30)	13	88.92	57.42	98.00
		PIII(D180)	14	94.29	60.85	80.00
p24	HIV-CQ	PRE	13	95.92	91.03	68.00
		PIII(D7)	12	99.00	76.07	93.50
		PIII(D14)	13	89.77	48.10	83.00
		PIII(D30)	11	120.91	64.37	120.00
		PIII(D180)	13	67.38	55.15	62.00
	HIV	PRE	14	90.14	83.34	77.50
		PIII(D7)	13	211.92	495.61	54.00
		PIII(D14)	13	90.23	57.94	91.00
		PIII(D30)	13	136.92	190.41	81.00
		PIII(D180)	14	57.86	51.37	45.00
pool_F4Co	HIV-CQ	PRE	13	83.00	49.84	76.00
		PIII(D7)	12	203.75	163.82	218.50
		PIII(D14)	13	121.46	101.06	92.00
		PIII(D30)	11	94.09	108.98	68.00
		PIII(D180)	13	98.54	88.03	65.00
	HIV	PRE	14	216.93	238.47	148.00
		PIII(D7)	13	148.31	125.14	129.00
		PIII(D14)	13	125.38	70.74	118.00
		PIII(D30)	13	154.00	137.14	122.00
		PIII(D180)	14	73.21	39.47	74.00
f4co_est	HIV-CQ	PRE	13	426.46	288.64	373.00
		PIII(D7)	12	533.25	446.08	448.50
		PIII(D14)	13	448.54	182.31	478.00
		PIII(D30)	11	322.27	163.49	290.00
		PIII(D180)	13	254.15	188.79	226.00
	HIV	PRE	14	457.43	337.37	398.00
		PIII(D7)	13	793.92	1287.22	451.00
		PIII(D14)	13	467.31	252.48	450.00
		PIII(D30)	13	418.54	270.92	380.00
		PIII(D180)	14	311.57	138.92	287.50

N = number of subjects with available results

SD = Standard Deviation

pool_F4co = Frequency of CD8⁺ T-cells expressing cytokines after in vitro stimulation with a peptide pool covering the complete sequence of the F4co fusion antigen.

F4co_est = Frequency of CD8⁺ T-cells expressing cytokines in response to the F4co fusion protein (all antigens) was estimated by adding individual frequencies of CD8⁺ T-cells to each of the 4 antigens (RT, Nef, p17, p24)

PRE = Pre Dose 3, i.e. Pre-Booster Dose

PIII(D7) = Day 7 Post Dose 3

PIII(D14) = Day 14 Post Dose 3

PIII(D30) = Day 30 Post Dose 3

PIII(D180) = Day 180 Post Dose 3

Secondary Outcome Variable(s): Cytokine/marker co-expression profile of the HIV vaccine- and each antigen-specific CD8⁺ T cells (ATP cohort for immunogenicity)

Stimulating Ag	Expressed Marker	Group	Activity	N	Mean	SD	Median
RT	CD40L+	HIV-CQ	PRE	13	152.46	127.05	146.00
			PIII(D7)	12	158.00	157.31	121.50
			PIII(D14)	13	110.23	102.06	91.00
			PIII(D30)	11	141.73	169.32	113.00
			PIII(D180)	13	65.31	97.47	1.00
		HIV	PRE	14	118.50	131.21	123.00
			PIII(D7)	13	232.54	224.30	168.00
			PIII(D14)	13	67.38	93.09	1.00
			PIII(D30)	13	95.15	109.00	27.00
			PIII(D180)	14	93.29	111.78	52.50
	IL2+	HIV-CQ	PRE	13	36.15	39.06	31.00
			PIII(D7)	12	151.08	421.97	32.50
			PIII(D14)	13	61.62	69.08	64.00
			PIII(D30)	11	22.18	26.94	3.00
			PIII(D180)	13	13.46	22.63	1.00
		HIV	PRE	14	68.07	114.34	1.00
			PIII(D7)	13	48.38	91.78	1.00
			PIII(D14)	13	49.00	58.07	32.00
			PIII(D30)	13	17.62	27.08	1.00
			PIII(D180)	14	22.29	39.01	1.00
	TNF+	HIV-CQ	PRE	13	36.54	84.51	1.00
			PIII(D7)	12	11.50	18.59	1.00
			PIII(D14)	13	25.15	43.94	1.00
			PIII(D30)	11	13.27	17.61	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	24.21	54.05	1.00
			PIII(D7)	13	48.08	54.12	34.00
			PIII(D14)	13	20.62	34.40	1.00
			PIII(D30)	13	16.08	33.26	1.00
			PIII(D180)	14	2.43	5.06	1.00
	IFN+	HIV-CQ	PRE	13	19.46	28.86	1.00
			PIII(D7)	12	24.33	40.41	1.00
			PIII(D14)	13	18.31	21.46	14.00
			PIII(D30)	11	15.18	17.80	4.00
			PIII(D180)	13	4.00	7.79	1.00
		HIV	PRE	14	36.93	84.09	1.00
			PIII(D7)	13	41.38	86.65	1.00
			PIII(D14)	13	9.46	21.51	1.00
			PIII(D30)	13	10.23	22.71	1.00
			PIII(D180)	14	12.43	20.72	1.00
	CD40L+IL2+	HIV-CQ	PRE	13	2.92	4.70	1.00
			PIII(D7)	12	1.00	0.00	1.00

			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	4.77	9.58	1.00
			PIII(D14)	13	2.46	5.27	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+TNF+	HIV-CQ	PRE	13	6.00	18.03	1.00
			PIII(D7)	12	6.67	13.30	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	3.38	8.60	1.00
			PIII(D14)	13	3.38	8.60	1.00
			PIII(D30)	13	2.31	4.71	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+IFN+	HIV-CQ	PRE	13	3.00	7.21	1.00
			PIII(D7)	12	4.67	9.76	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	4.18	10.55	1.00
			PIII(D180)	13	5.08	10.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	5.15	7.90	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	3.00	7.48	1.00
	IL2+TNF+	HIV-CQ	PRE	13	3.00	7.21	1.00
			PIII(D7)	12	6.25	14.14	1.00
			PIII(D14)	13	3.62	9.43	1.00
			PIII(D30)	11	4.09	10.25	1.00
			PIII(D180)	13	2.85	6.66	1.00
		HIV	PRE	14	6.00	10.01	1.00
			PIII(D7)	13	6.38	13.24	1.00
			PIII(D14)	13	13.46	23.75	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	IL2+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	2.23	4.44	1.00
			PIII(D14)	13	3.62	9.43	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	TNF+IFN+	HIV-CQ	PRE	13	3.85	10.26	1.00
			PIII(D7)	12	17.83	27.98	1.00
			PIII(D14)	13	3.23	8.04	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	3.43	9.09	1.00
			PIII(D7)	13	14.62	26.38	1.00

			PIII(D14)	13	2.46	5.27	1.00
			PIII(D30)	13	19.15	27.13	1.00
			PIII(D180)	14	6.07	14.42	1.00
	CD40L+IL2+TNF+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	4.67	9.76	1.00
			PIII(D14)	13	2.77	6.38	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	2.71	6.41	1.00
			PIII(D7)	13	3.54	6.20	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	2.69	6.10	1.00
			PIII(D180)	14	3.00	7.48	1.00
	CD40L+IL2+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	4.08	10.68	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	3.00	7.21	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	4.67	9.76	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	4.36	7.51	1.00
			PIII(D180)	13	2.85	6.66	1.00
		HIV	PRE	14	3.36	8.82	1.00
			PIII(D7)	13	2.31	4.71	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	3.54	9.15	1.00
			PIII(D180)	14	1.00	0.00	1.00
	IL2+TNF+IFN+	HIV-CQ	PRE	13	4.77	10.52	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	3.38	8.60	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	7.25	12.44	1.00
			PIII(D14)	13	4.62	8.88	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	3.00	7.48	1.00
Nef	CD40L+	HIV-CQ	PRE	13	179.23	222.24	155.00
			PIII(D7)	12	102.00	83.66	90.50

			PIII(D14)	13	156.54	100.98	122.00
			PIII(D30)	11	208.91	219.37	191.00
			PIII(D180)	13	147.92	143.34	134.00
		HIV	PRE	14	115.43	143.37	72.50
			PIII(D7)	13	173.31	155.37	173.00
			PIII(D14)	13	54.15	83.93	10.00
			PIII(D30)	13	66.46	90.59	30.00
			PIII(D180)	14	114.07	183.04	43.50
	IL2+	HIV-CQ	PRE	13	35.77	62.24	1.00
			PIII(D7)	12	29.92	35.93	22.00
			PIII(D14)	13	39.85	36.39	40.00
			PIII(D30)	11	16.45	33.11	1.00
			PIII(D180)	13	25.08	51.81	1.00
		HIV	PRE	14	59.64	113.00	9.50
			PIII(D7)	13	22.77	37.18	1.00
			PIII(D14)	13	49.08	43.83	59.00
			PIII(D30)	13	36.54	49.77	1.00
			PIII(D180)	14	54.14	59.45	26.50
	TNF+	HIV-CQ	PRE	13	16.15	40.02	1.00
			PIII(D7)	12	22.83	39.54	1.00
			PIII(D14)	13	22.77	36.31	1.00
			PIII(D30)	11	24.91	41.30	1.00
			PIII(D180)	13	5.00	9.80	1.00
		HIV	PRE	14	9.43	18.90	1.00
			PIII(D7)	13	27.00	31.94	4.00
			PIII(D14)	13	3.15	7.77	1.00
			PIII(D30)	13	28.15	39.37	1.00
			PIII(D180)	14	9.57	17.88	1.00
	IFN+	HIV-CQ	PRE	13	17.77	40.63	1.00
			PIII(D7)	12	12.83	17.55	1.00
			PIII(D14)	13	17.69	26.08	1.00
			PIII(D30)	11	14.18	15.98	2.00
			PIII(D180)	13	16.38	35.64	1.00
		HIV	PRE	14	15.43	26.74	1.00
			PIII(D7)	13	1.92	3.33	1.00
			PIII(D14)	13	8.46	19.15	1.00
			PIII(D30)	13	17.23	30.12	1.00
			PIII(D180)	14	15.50	26.37	1.00
	CD40L+IL2+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	5.25	14.72	1.00
			PIII(D14)	13	9.92	24.99	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	2.77	6.38	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+TNF+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	4.08	10.68	1.00
			PIII(D14)	13	2.92	6.93	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	3.43	9.09	1.00
			PIII(D7)	13	3.46	8.88	1.00

			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	2.54	5.55	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+IFN+	HIV-CQ	PRE	13	7.15	15.93	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	3.92	7.54	1.00
			PIII(D30)	11	2.55	5.13	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	10.15	18.70	1.00
			PIII(D14)	13	10.23	16.70	1.00
			PIII(D30)	13	4.85	9.61	1.00
			PIII(D180)	14	4.57	9.48	1.00
	IL2+TNF+	HIV-CQ	PRE	13	3.77	9.98	1.00
			PIII(D7)	12	2.92	6.64	1.00
			PIII(D14)	13	5.92	12.13	1.00
			PIII(D30)	11	10.18	16.63	1.00
			PIII(D180)	13	2.00	3.61	1.00
		HIV	PRE	14	19.64	27.53	1.00
			PIII(D7)	13	11.77	28.56	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	6.92	21.36	1.00
			PIII(D180)	14	2.29	4.81	1.00
	IL2+IFN+	HIV-CQ	PRE	13	5.69	16.92	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	2.46	5.27	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	TNF+IFN+	HIV-CQ	PRE	13	3.77	9.98	1.00
			PIII(D7)	12	2.17	4.04	1.00
			PIII(D14)	13	6.77	11.03	1.00
			PIII(D30)	11	4.64	8.20	1.00
			PIII(D180)	13	5.92	12.45	1.00
		HIV	PRE	14	2.79	6.68	1.00
			PIII(D7)	13	2.46	5.27	1.00
			PIII(D14)	13	6.77	11.17	1.00
			PIII(D30)	13	6.08	18.31	1.00
			PIII(D180)	14	6.14	14.68	1.00
	CD40L+IL2+TNF+	HIV-CQ	PRE	13	1.92	3.33	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+IL2+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	5.75	11.19	1.00

			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	2.54	5.55	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	2.82	6.03	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	2.36	5.08	1.00
			PIII(D7)	13	3.38	8.60	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	IL2+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	3.62	9.43	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	3.83	9.81	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	4.23	11.65	1.00
			PIII(D180)	14	1.00	0.00	1.00
p17	CD40L+	HIV-CQ	PRE	13	116.23	140.29	65.00
			PIII(D7)	12	79.75	93.05	40.50
			PIII(D14)	13	81.00	92.51	1.00
			PIII(D30)	11	70.27	102.24	7.00
			PIII(D180)	13	53.38	57.94	44.00
		HIV	PRE	14	83.79	127.04	1.00
			PIII(D7)	13	104.77	153.12	34.00
			PIII(D14)	13	43.77	98.09	1.00
			PIII(D30)	13	84.46	109.33	13.00
			PIII(D180)	14	48.71	78.15	4.50
	IL2+	HIV-CQ	PRE	13	14.77	17.81	1.00
			PIII(D7)	12	16.42	17.75	7.50
			PIII(D14)	13	44.23	57.44	25.00
			PIII(D30)	11	7.09	13.46	1.00
			PIII(D180)	13	48.38	75.39	10.00
		HIV	PRE	14	21.36	44.63	1.00
			PIII(D7)	13	21.54	21.80	21.00

			PIII(D14)	13	39.31	44.94	33.00
			PIII(D30)	13	15.69	24.30	1.00
			PIII(D180)	14	41.93	37.21	39.00
	TNF+	HIV-CQ	PRE	13	35.46	50.80	1.00
			PIII(D7)	12	24.08	36.55	1.00
			PIII(D14)	13	33.77	58.84	1.00
			PIII(D30)	11	6.18	11.53	1.00
			PIII(D180)	13	3.85	10.26	1.00
		HIV	PRE	14	18.36	35.09	1.00
			PIII(D7)	13	257.92	829.58	21.00
			PIII(D14)	13	96.85	270.62	1.00
			PIII(D30)	13	20.85	28.22	1.00
			PIII(D180)	14	12.21	24.59	1.00
	IFN+	HIV-CQ	PRE	13	19.15	25.93	1.00
			PIII(D7)	12	18.42	32.85	1.00
			PIII(D14)	13	6.38	10.69	1.00
			PIII(D30)	11	16.64	36.46	1.00
			PIII(D180)	13	19.15	25.59	3.00
		HIV	PRE	14	13.21	21.94	1.00
			PIII(D7)	13	5.31	8.49	1.00
			PIII(D14)	13	15.15	23.36	1.00
			PIII(D30)	13	16.46	25.47	1.00
			PIII(D180)	14	14.21	22.69	1.00
	CD40L+IL2+	HIV-CQ	PRE	13	3.38	8.60	1.00
			PIII(D7)	12	4.58	9.49	1.00
			PIII(D14)	13	2.69	6.10	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	12.79	35.28	1.00
			PIII(D7)	13	2.23	4.44	1.00
			PIII(D14)	13	5.00	14.42	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+TNF+	HIV-CQ	PRE	13	4.69	13.31	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	2.62	5.82	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	6.79	15.91	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	3.38	8.60	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+IFN+	HIV-CQ	PRE	13	1.92	3.33	1.00
			PIII(D7)	12	4.25	8.08	1.00
			PIII(D14)	13	4.31	8.08	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	3.00	7.21	1.00
		HIV	PRE	14	4.93	10.41	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	2.46	5.27	1.00
			PIII(D30)	13	3.54	9.15	1.00
			PIII(D180)	14	3.43	9.09	1.00
	IL2+TNF+	HIV-CQ	PRE	13	10.46	20.75	1.00
			PIII(D7)	12	1.00	0.00	1.00

			PIII(D14)	13	8.15	25.79	1.00
			PIII(D30)	11	2.82	6.03	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	3.79	10.42	1.00
			PIII(D7)	13	2.46	5.27	1.00
			PIII(D14)	13	6.85	21.08	1.00
			PIII(D30)	13	11.38	18.88	1.00
			PIII(D180)	14	3.07	7.75	1.00
	IL2+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	3.67	9.24	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	2.71	6.41	1.00
			PIII(D7)	13	2.31	4.71	1.00
			PIII(D14)	13	1.00	0.00	1.00
	TNF+IFN+	HIV-CQ	PRE	13	11.31	30.91	1.00
			PIII(D7)	12	7.92	14.56	1.00
			PIII(D14)	13	2.69	6.10	1.00
			PIII(D30)	11	5.64	15.38	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	6.93	12.42	1.00
			PIII(D7)	13	7.23	17.98	1.00
			PIII(D14)	13	2.92	6.93	1.00
	CD40L+IL2+TNF+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	3.67	9.24	1.00
			PIII(D14)	13	2.69	6.10	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
	CD40L+IL2+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	3.33	8.08	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
	CD40L+TNF+IFN+	HIV-CQ	PRE	13	5.69	12.23	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00

			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	3.62	9.43	1.00
			PIII(D180)	14	1.00	0.00	1.00
	IL2+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	3.29	8.55	1.00
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	3.33	8.08	1.00
			PIII(D14)	13	2.54	5.55	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	3.29	8.55	1.00
p24	CD40L+	HIV-CQ	PRE	13	149.54	116.25	178.00
			PIII(D7)	12	72.67	67.26	61.50
			PIII(D14)	13	100.15	92.79	100.00
			PIII(D30)	11	82.82	152.41	1.00
			PIII(D180)	13	101.15	134.50	16.00
		HIV	PRE	14	112.93	105.51	103.50
			PIII(D7)	13	130.54	175.21	37.00
			PIII(D14)	13	66.31	75.24	30.00
			PIII(D30)	13	84.62	94.41	59.00
			PIII(D180)	14	26.57	57.80	1.00
	IL2+	HIV-CQ	PRE	13	12.46	18.40	1.00
			PIII(D7)	12	31.92	50.38	7.50
			PIII(D14)	13	31.08	48.19	1.00
			PIII(D30)	11	27.45	46.13	1.00
			PIII(D180)	13	34.31	48.12	1.00
		HIV	PRE	14	17.14	31.91	1.00
			PIII(D7)	13	26.31	60.54	1.00
			PIII(D14)	13	27.38	34.77	1.00
			PIII(D30)	13	55.00	79.52	32.00
			PIII(D180)	14	16.36	22.54	1.00
	TNF+	HIV-CQ	PRE	13	41.62	60.05	1.00
			PIII(D7)	12	27.67	55.93	1.00
			PIII(D14)	13	21.62	25.02	1.00
			PIII(D30)	11	29.73	39.95	1.00
			PIII(D180)	13	4.46	8.74	1.00
		HIV	PRE	14	20.07	66.08	1.00
			PIII(D7)	13	153.62	440.62	27.00
			PIII(D14)	13	24.46	60.29	1.00
			PIII(D30)	13	33.54	79.89	1.00
			PIII(D180)	14	10.79	17.79	1.00
	IFN+	HIV-CQ	PRE	13	22.69	28.37	5.00
			PIII(D7)	12	18.00	22.83	1.00

			PIII(D14)	13	18.38	21.23	1.00
			PIII(D30)	11	27.09	25.44	25.00
			PIII(D180)	13	9.31	13.02	1.00
		HIV	PRE	14	27.50	37.54	1.00
			PIII(D7)	13	7.92	17.02	1.00
			PIII(D14)	13	13.08	26.29	1.00
			PIII(D30)	13	23.46	35.39	1.00
			PIII(D180)	14	13.50	24.75	1.00
	CD40L+IL2+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	3.00	7.21	1.00
	CD40L+TNF+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	3.75	9.53	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	5.82	10.78	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	3.00	7.21	1.00
	CD40L+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	3.67	9.24	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	6.18	12.62	1.00
			PIII(D180)	13	4.69	13.31	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	3.23	5.48	1.00
			PIII(D14)	13	3.00	7.21	1.00
	IL2+TNF+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	2.00	3.61	1.00
			PIII(D30)	11	8.00	15.70	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	8.23	21.72	1.00
	IL2+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	3.23	8.04	1.00
		HIV	PRE	14	2.79	6.68	1.00
			PIII(D7)	13	1.00	0.00	1.00

			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	TNF+IFN+	HIV-CQ	PRE	13	2.08	3.59	1.00
			PIII(D7)	12	1.92	3.18	1.00
			PIII(D14)	13	5.92	12.45	1.00
			PIII(D30)	11	9.64	19.37	1.00
			PIII(D180)	13	3.38	8.30	1.00
		HIV	PRE	14	13.64	30.11	1.00
			PIII(D7)	13	10.31	22.45	1.00
			PIII(D14)	13	2.08	3.88	1.00
			PIII(D30)	13	12.23	17.64	1.00
			PIII(D180)	14	7.21	23.25	1.00
	CD40L+IL2+TNF+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	4.00	10.39	1.00
			PIII(D14)	13	2.77	6.38	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+IL2+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	2.08	3.75	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	IL2+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	2.54	5.55	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	1.00	0.00	1.00

			PIII(D14)	13	1.00	0.00	1.00	
			PIII(D30)	11	1.00	0.00	1.00	
			PIII(D180)	13	1.00	0.00	1.00	
		HIV	PRE	14	1.00	0.00	1.00	
			PIII(D7)	13	1.00	0.00	1.00	
			PIII(D14)	13	1.00	0.00	1.00	
			PIII(D30)	13	1.00	0.00	1.00	
			PIII(D180)	14	1.00	0.00	1.00	
POOL_F4C O	CD40L+	HIV-CQ	PRE	13	148.54	156.55	114.00	
			PIII(D7)	12	159.75	150.64	141.50	
			PIII(D14)	13	114.54	79.01	113.00	
			PIII(D30)	11	154.73	142.41	84.00	
			PIII(D180)	13	79.69	75.84	61.00	
		HIV	PRE	14	138.79	138.78	105.00	
			PIII(D7)	13	183.54	134.79	185.00	
			PIII(D14)	13	85.46	135.06	1.00	
			PIII(D30)	13	121.08	140.06	69.00	
			PIII(D180)	14	96.64	104.02	48.00	
		IL2+	HIV-CQ	PRE	13	23.54	37.77	1.00
				PIII(D7)	12	81.42	119.82	26.00
				PIII(D14)	13	40.92	55.97	31.00
				PIII(D30)	11	46.09	77.60	1.00
				PIII(D180)	13	49.46	67.33	27.00
			HIV	PRE	14	70.36	159.14	22.00
	PIII(D7)			13	41.08	54.12	3.00	
	PIII(D14)			13	52.85	52.57	32.00	
	PIII(D30)			13	71.38	124.51	20.00	
	PIII(D180)			14	25.86	32.88	1.00	
	TNF+	HIV-CQ	PRE	13	21.46	36.97	1.00	
			PIII(D7)	12	24.08	45.38	1.00	
			PIII(D14)	13	22.85	47.79	2.00	
			PIII(D30)	11	13.45	22.70	1.00	
			PIII(D180)	13	6.92	11.32	1.00	
		HIV	PRE	14	33.14	67.69	1.00	
			PIII(D7)	13	23.54	32.86	5.00	
			PIII(D14)	13	29.23	40.28	1.00	
PIII(D30)			13	25.92	38.30	1.00		
PIII(D180)			14	2.29	4.81	1.00		
IFN+	HIV-CQ	PRE	13	8.77	11.10	1.00		
		PIII(D7)	12	17.58	34.71	1.00		
		PIII(D14)	13	16.00	17.91	5.00		
		PIII(D30)	11	11.18	22.76	1.00		
		PIII(D180)	13	20.69	32.80	1.00		
	HIV	PRE	14	56.00	82.29	28.00		
		PIII(D7)	13	29.62	44.51	14.00		
		PIII(D14)	13	14.31	21.01	1.00		
		PIII(D30)	13	21.77	23.16	17.00		
		PIII(D180)	14	19.43	28.50	1.00		
CD40L+IL2+	HIV-CQ	PRE	13	1.00	0.00	1.00		
		PIII(D7)	12	21.50	36.75	1.00		
		PIII(D14)	13	6.23	12.77	1.00		
		PIII(D30)	11	1.00	0.00	1.00		
		PIII(D180)	13	1.00	0.00	1.00		
	HIV	PRE	14	1.00	0.00	1.00		
		PIII(D7)	13	1.00	0.00	1.00		

			PIII(D14)	13	1.00	0.00	1.00	
			PIII(D30)	13	1.00	0.00	1.00	
			PIII(D180)	14	1.00	0.00	1.00	
	CD40L+TNF+	HIV-CQ	PRE	13	7.46	22.12	1.00	
			PIII(D7)	12	6.33	12.72	1.00	
			PIII(D14)	13	2.77	6.38	1.00	
			PIII(D30)	11	1.00	0.00	1.00	
			PIII(D180)	13	1.00	0.00	1.00	
		HIV	PRE	14	3.57	6.55	1.00	
			PIII(D7)	13	7.92	19.74	1.00	
			PIII(D14)	13	3.62	9.43	1.00	
	CD40L+IFN+	HIV-CQ	PIII(D30)	13	1.00	0.00	1.00	
			PIII(D180)	14	1.00	0.00	1.00	
			HIV	PRE	14	4.79	10.06	1.00
				PIII(D7)	13	4.92	9.94	1.00
				PIII(D14)	13	1.00	0.00	1.00
		PIII(D30)	13	2.69	6.10	1.00		
			PIII(D180)	14	5.43	11.37	1.00	
				IL2+TNF+	HIV-CQ	PRE	13	1.00
	PIII(D7)	12				7.58	15.90	1.00
	PIII(D14)	13	17.77			31.16	1.00	
PIII(D30)	11	6.45	13.46			1.00		
PIII(D180)	13	1.00	0.00			1.00		
HIV	PRE	14	12.07		25.50	1.00		
	PIII(D7)	13	6.15		10.00	1.00		
	PIII(D14)	13	1.00		0.00	1.00		
IL2+IFN+	HIV-CQ	PIII(D30)	13	1.00	0.00	1.00		
		PIII(D180)	14	2.29	4.81	1.00		
		HIV	PRE	14	3.43	9.09	1.00	
			PIII(D7)	13	7.08	17.45	1.00	
			PIII(D14)	13	2.46	5.27	1.00	
	PIII(D30)	13	8.77	14.83	1.00			
		PIII(D180)	14	1.00	0.00	1.00		
			TNF+IFN+	HIV-CQ	PRE	13	9.15	20.70
PIII(D7)	12				9.25	15.33	1.00	
PIII(D14)	13	3.62			9.43	1.00		
PIII(D30)	11	6.00			11.50	1.00		
PIII(D180)	13	2.77			6.38	1.00		
HIV	PRE	14		19.07	37.26	1.00		
	PIII(D7)	13		12.85	21.04	1.00		
	PIII(D14)	13		6.62	12.07	1.00		
CD40L+IL2+TNF+	HIV-CQ	PIII(D30)	13	10.69	14.87	1.00		
		PIII(D180)	14	5.50	11.44	1.00		
		PRE	13	1.00	0.00	1.00		
		PIII(D7)	12	7.00	11.82	1.00		

			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	5.46	10.90	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	5.54	11.88	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	2.93	7.22	1.00
	CD40L+IL2+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	3.00	7.48	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	1.00	0.00	1.00
	CD40L+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	2.08	3.75	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	6.14	13.10	1.00
			PIII(D7)	13	6.23	10.48	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	2.38	4.99	1.00
			PIII(D180)	14	1.00	0.00	1.00
	IL2+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	5.42	10.49	1.00
			PIII(D14)	13	3.08	7.49	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	2.54	5.55	1.00
			PIII(D14)	13	1.00	0.00	1.00
			PIII(D30)	13	1.00	0.00	1.00
			PIII(D180)	14	3.50	9.35	1.00
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	3.42	5.68	1.00
			PIII(D14)	13	3.23	8.04	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	5.23	10.38	1.00
		HIV	PRE	14	2.36	5.08	1.00
			PIII(D7)	13	3.38	8.60	1.00
			PIII(D14)	13	4.77	9.47	1.00
			PIII(D30)	13	4.38	8.42	1.00
			PIII(D180)	14	1.00	0.00	1.00
F4CO_EST	CD40L+	HIV-CQ	PRE	13	597.46	526.43	608.00
			PIII(D7)	12	412.42	264.76	359.50
			PIII(D14)	13	447.92	292.53	375.00
			PIII(D30)	11	503.73	535.62	347.00
			PIII(D180)	13	367.77	344.50	278.00
		HIV	PRE	14	430.64	417.04	301.00
			PIII(D7)	13	641.15	590.40	532.00

			PIII(D14)	13	231.62	202.74	201.00
			PIII(D30)	13	330.69	316.21	242.00
			PIII(D180)	14	282.64	342.22	150.00
	IL2+	HIV-CQ	PRE	13	99.15	94.77	77.00
			PIII(D7)	12	229.33	408.34	129.00
			PIII(D14)	13	176.77	149.41	122.00
			PIII(D30)	11	73.18	81.85	22.00
			PIII(D180)	13	121.23	138.88	85.00
		HIV	PRE	14	166.21	243.11	64.00
			PIII(D7)	13	119.00	118.60	84.00
			PIII(D14)	13	164.77	130.77	141.00
			PIII(D30)	13	124.85	138.57	73.00
			PIII(D180)	14	134.71	104.07	127.50
	TNF+	HIV-CQ	PRE	13	129.77	154.22	112.00
			PIII(D7)	12	86.08	83.68	57.50
			PIII(D14)	13	103.31	122.89	55.00
			PIII(D30)	11	74.09	87.75	4.00
			PIII(D180)	13	14.31	14.20	4.00
		HIV	PRE	14	72.07	155.33	9.50
			PIII(D7)	13	486.62	1250.95	176.00
			PIII(D14)	13	145.08	292.41	4.00
			PIII(D30)	13	98.62	108.32	67.00
			PIII(D180)	14	35.00	40.71	14.50
	IFN+	HIV-CQ	PRE	13	79.08	81.02	60.00
			PIII(D7)	12	73.58	84.09	36.00
			PIII(D14)	13	60.77	32.60	56.00
			PIII(D30)	11	73.09	61.26	52.00
			PIII(D180)	13	48.85	53.60	30.00
		HIV	PRE	14	93.07	108.90	58.50
			PIII(D7)	13	56.54	85.92	29.00
			PIII(D14)	13	46.15	48.02	21.00
			PIII(D30)	13	67.38	84.62	22.00
			PIII(D180)	14	55.64	76.70	23.50
	CD40L+IL2+	HIV-CQ	PRE	13	8.31	9.28	4.00
			PIII(D7)	12	11.83	16.54	4.00
			PIII(D14)	13	14.62	25.08	4.00
			PIII(D30)	11	4.00	0.00	4.00
			PIII(D180)	13	5.77	6.38	4.00
		HIV	PRE	14	15.79	35.28	4.00
			PIII(D7)	13	9.00	10.07	4.00
			PIII(D14)	13	11.46	21.84	4.00
			PIII(D30)	13	4.00	0.00	4.00
			PIII(D180)	14	4.00	0.00	4.00
	CD40L+TNF+	HIV-CQ	PRE	13	12.69	21.50	4.00
			PIII(D7)	12	15.50	17.06	4.00
			PIII(D14)	13	7.54	8.68	4.00
			PIII(D30)	11	8.82	10.78	4.00
			PIII(D180)	13	4.00	0.00	4.00
		HIV	PRE	14	12.21	17.48	4.00
			PIII(D7)	13	8.85	11.83	4.00
			PIII(D14)	13	10.77	18.08	4.00
			PIII(D30)	13	6.85	6.97	4.00
			PIII(D180)	14	4.00	0.00	4.00
	CD40L+IFN+	HIV-CQ	PRE	13	13.08	18.05	4.00
			PIII(D7)	12	13.58	13.41	4.00

			PIII(D14)	13	10.23	10.06	4.00
			PIII(D30)	11	13.91	22.98	4.00
			PIII(D180)	13	13.77	16.22	4.00
		HIV	PRE	14	7.93	10.41	4.00
			PIII(D7)	13	19.54	21.90	5.00
			PIII(D14)	13	16.69	18.53	4.00
			PIII(D30)	13	10.38	12.45	4.00
			PIII(D180)	14	12.00	13.56	4.00
	IL2+TNF+	HIV-CQ	PRE	13	25.31	33.43	4.00
			PIII(D7)	12	11.17	20.56	4.00
			PIII(D14)	13	19.69	27.16	4.00
			PIII(D30)	11	25.09	31.89	4.00
			PIII(D180)	13	6.85	7.30	4.00
		HIV	PRE	14	30.43	26.70	28.00
			PIII(D7)	13	21.62	29.02	4.00
			PIII(D14)	13	29.54	63.85	4.00
	IL2+IFN+	HIV-CQ	PIII(D30)	13	23.00	34.15	4.00
			PIII(D180)	14	7.36	8.80	4.00
		HIV	PRE	14	7.50	13.10	4.00
			PIII(D7)	13	8.00	7.63	4.00
			PIII(D14)	13	6.62	9.43	4.00
		HIV	PIII(D30)	13	4.00	0.00	4.00
			PIII(D180)	14	4.00	0.00	4.00
	TNF+IFN+	HIV-CQ	PRE	13	21.00	50.66	4.00
			PIII(D7)	12	29.83	32.21	15.50
			PIII(D14)	13	18.62	22.82	4.00
			PIII(D30)	11	20.91	37.13	4.00
			PIII(D180)	13	11.31	14.09	4.00
		HIV	PRE	14	26.79	39.64	4.00
			PIII(D7)	13	34.62	45.79	23.00
			PIII(D14)	13	14.23	16.55	4.00
	CD40L+IL2+TNF+	HIV-CQ	PIII(D30)	13	47.85	54.34	27.00
			PIII(D180)	14	24.00	44.41	4.00
		HIV	PRE	13	4.92	3.33	4.00
			PIII(D7)	12	13.33	15.03	4.00
			PIII(D14)	13	9.23	9.94	4.00
		HIV	PIII(D30)	11	4.00	0.00	4.00
			PIII(D180)	13	4.00	0.00	4.00
			PRE	14	5.71	6.41	4.00
	CD40L+IL2+IFN+	HIV-CQ	PIII(D7)	13	6.54	6.20	4.00
			PIII(D14)	13	4.00	0.00	4.00
			PIII(D30)	13	5.69	6.10	4.00
			PIII(D180)	14	8.29	10.92	4.00
		HIV	PRE	13	4.00	0.00	4.00
			PIII(D7)	12	14.17	15.26	4.00
			PIII(D14)	13	4.00	0.00	4.00
		HIV	PIII(D30)	11	4.00	0.00	4.00
			PIII(D180)	13	4.00	0.00	4.00
			PRE	14	4.00	0.00	4.00
		HIV	PIII(D7)	13	4.00	0.00	4.00

	CD40L+TNF+IFN+		PIII(D14)	13	6.00	7.21	4.00
			PIII(D30)	13	5.54	5.55	4.00
			PIII(D180)	14	4.00	0.00	4.00
		HIV-CQ	PRE	13	8.69	12.23	4.00
			PIII(D7)	12	8.75	10.04	4.00
			PIII(D14)	13	4.00	0.00	4.00
			PIII(D30)	11	9.18	12.62	4.00
			PIII(D180)	13	5.85	6.66	4.00
		HIV	PRE	14	7.71	9.83	4.00
			PIII(D7)	13	7.69	9.46	4.00
			PIII(D14)	13	4.00	0.00	4.00
			PIII(D30)	13	9.15	12.58	4.00
			PIII(D180)	14	4.00	0.00	4.00
	IL2+TNF+IFN+	HIV-CQ	PRE	13	7.77	10.52	4.00
			PIII(D7)	12	4.00	0.00	4.00
			PIII(D14)	13	6.62	9.43	4.00
			PIII(D30)	11	4.00	0.00	4.00
			PIII(D180)	13	4.00	0.00	4.00
		HIV	PRE	14	4.00	0.00	4.00
			PIII(D7)	13	7.92	9.84	4.00
			PIII(D14)	13	4.00	0.00	4.00
			PIII(D30)	13	4.00	0.00	4.00
			PIII(D180)	14	6.29	8.55	4.00
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	4.00	0.00	4.00
			PIII(D7)	12	15.42	27.87	4.00
			PIII(D14)	13	9.15	12.95	4.00
			PIII(D30)	11	4.00	0.00	4.00
			PIII(D180)	13	4.00	0.00	4.00
		HIV	PRE	14	4.00	0.00	4.00
			PIII(D7)	13	4.00	0.00	4.00
			PIII(D14)	13	4.00	0.00	4.00
			PIII(D30)	13	7.23	11.65	4.00
			PIII(D180)	14	8.29	10.92	4.00

N = number of subjects with available results

SD = Standard Deviation

POOL_F4CO = Frequency of CD8+ T-cells expressing cytokines after *in vitro* stimulation with a peptide pool covering the complete sequence of the F4co fusion antigen.

F4CO_EST = Frequency of CD8+ T cells expressing markers in response to the F4co fusion protein (all antigens) was estimated by adding individual frequencies of CD8+ T cells to each of the 4 antigens (RT, nef, p17, p24)

PRE = Pre Dose 3, i.e. Pre-Booster Dose

PIII(D7) = Day 7 Post Dose 3

PIII(D14) = Day 14 Post Dose 3

PIII(D30) = Day 30 Post Dose 3

PIII(D180) = Day 180 Post Dose 3

Secondary Outcome Variable(s): Frequency (responder rate) of CD4+ T-cells expressing at least 2 cytokines including IL-2: Number and percentage of responders to at least 1, 2, 3 and all 4 antigens (ATP cohort for immunogenicity)

						95% CI	
Group	Timing	Number of antigens	N	n	%	LL%	UL
HIV-QC	PRE	At least 1 antigen	13	12	92.3	64.0	99.8
		At least 2 antigens	13	10	76.9	46.2	95.0
		At least 3 antigens	13	6	46.2	19.2	74.9
		All 4 antigens	13	1	7.7	0.2	36.0
	PIII(D7)	At least 1 antigen	12	12	100	73.5	100
		At least 2 antigens	12	11	91.7	61.5	99.8
		At least 3 antigens	12	10	83.3	51.6	97.9

	PIII(D14)	All 4 antigens	12	6	50.0	21.1	78.9
		At least 1 antigen	13	12	92.3	64.0	99.8
		At least 2 antigens	13	12	92.3	64.0	99.8
		At least 3 antigens	13	10	76.9	46.2	95.0
	PIII(D30)	All 4 antigens	13	6	46.2	19.2	74.9
		At least 1 antigen	11	8	72.7	39.0	94.0
		At least 2 antigens	11	7	63.6	30.8	89.1
		At least 3 antigens	11	7	63.6	30.8	89.1
	PIII(D180)	All 4 antigens	11	7	63.6	30.8	89.1
		At least 1 antigen	13	13	100	75.3	100
		At least 2 antigens	13	11	84.6	54.6	98.1
		At least 3 antigens	13	10	76.9	46.2	95.0
	PIII(D180)	All 4 antigens	13	3	23.1	5.0	53.8
		At least 1 antigen	14	11	78.6	49.2	95.3
		At least 2 antigens	14	11	78.6	49.2	95.3
		At least 3 antigens	14	4	28.6	8.4	58.1
HIV	PRE	All 4 antigens	14	3	21.4	4.7	50.8
		At least 1 antigen	13	12	92.3	64.0	99.8
		At least 2 antigens	13	11	84.6	54.6	98.1
		At least 3 antigens	13	10	76.9	46.2	95.0
	PIII(D7)	All 4 antigens	13	8	61.5	31.6	86.1
		At least 1 antigen	13	12	92.3	64.0	99.8
		At least 2 antigens	13	11	84.6	54.6	98.1
		At least 3 antigens	13	10	76.9	46.2	95.0
	PIII(D14)	All 4 antigens	13	8	61.5	31.6	86.1
		At least 1 antigen	13	12	92.3	64.0	99.8
		At least 2 antigens	13	11	84.6	54.6	98.1
		At least 3 antigens	13	10	76.9	46.2	95.0
	PIII(D30)	All 4 antigens	13	6	46.2	19.2	74.9
		At least 1 antigen	13	13	100	75.3	100
		At least 2 antigens	13	13	100	75.3	100
		At least 3 antigens	13	10	76.9	46.2	95.0
	PIII(D180)	All 4 antigens	13	6	46.2	19.2	74.9
		At least 1 antigen	14	14	100	76.8	100
		At least 2 antigens	14	13	92.9	66.1	99.8
		At least 3 antigens	14	9	64.3	35.1	87.2

N = number of subjects with available results to all 4 antigens
n/% = number/percentage of subjects in the specified category
95% CI = 95% CI confidence interval ; LL = Lower Limit, UL = Upper Limit
PRE = Pre Dose 3, i.e. Pre-Booster dose
PIII(D7) = Day 7 Post Dose 3
PIII(D14) = Day 14 Post Dose 3
PIII(D30) = Day 30 Post Dose 3
PIII(D180) = Day 180 Post Dose 3

Secondary Outcome Variable(s): Frequency (magnitude) of CD4⁺ T-cells expressing at least 2 cytokines including IL-2 :
Descriptive statistics (ATP cohort for immunogenicity)

Stimulating Ag	Group	Activity	N	Mean	SD	Median
RT	HIV-CQ	PRE	13	1027.85	736.71	846.00
		PIII(D7)	12	3228.75	2182.82	2407.00
		PIII(D14)	13	3981.54	4138.79	3162.00
		PIII(D30)	11	2516.73	2474.28	2088.00
		PIII(D180)	13	1763.62	1184.77	1205.00
	HIV	PRE	14	1308.14	1075.45	1125.50
		PIII(D7)	13	3763.38	2848.58	3286.00
		PIII(D14)	13	3473.46	2455.08	3461.00
		PIII(D30)	13	2714.77	1238.06	2459.00
nef	HIV-CQ	PIII(D180)	14	1954.79	1189.94	1684.00
		PRE	13	336.54	332.07	259.00

		PIII(D7)	12	1075.08	1645.21	586.50
		PIII(D14)	13	1321.00	1566.06	890.00
		PIII(D30)	11	722.00	726.90	627.00
		PIII(D180)	13	566.62	734.45	305.00
	HIV	PRE	14	322.29	308.94	161.00
		PIII(D7)	13	894.46	817.94	739.00
		PIII(D14)	13	972.92	1096.15	560.00
		PIII(D30)	13	632.23	590.99	386.00
p17	HIV-CQ	PIII(D180)	14	449.93	361.77	306.50
		PRE	13	197.00	146.74	154.00
		PIII(D7)	12	568.67	510.08	464.00
		PIII(D14)	13	1133.23	2269.33	453.00
	HIV	PIII(D30)	11	826.55	1279.21	397.00
		PIII(D180)	13	418.62	543.58	278.00
		PRE	14	335.50	336.24	176.00
		PIII(D7)	13	866.15	830.02	500.00
p24	HIV-CQ	PIII(D14)	13	951.62	1097.99	503.00
		PIII(D30)	13	713.38	689.38	346.00
		PIII(D180)	14	621.29	558.64	523.00
		PRE	13	470.00	279.16	477.00
	HIV	PIII(D7)	12	1120.42	846.39	872.50
		PIII(D14)	13	1448.15	1482.01	1198.00
		PIII(D30)	11	837.45	935.84	641.00
		PIII(D180)	13	640.69	366.84	530.00
POOL_F4CO	HIV-CQ	PRE	14	617.50	700.70	434.00
		PIII(D7)	13	1046.92	794.83	911.00
		PIII(D14)	13	1112.31	805.19	827.00
		PIII(D30)	13	974.77	780.28	793.00
	HIV	PIII(D180)	14	713.57	600.15	536.50
		PRE	13	1703.38	1145.64	1421.00
		PIII(D7)	12	5149.83	3577.03	3881.00
		PIII(D14)	13	6956.00	7869.20	4898.00
F4CO_EST	HIV-CQ	PIII(D30)	11	4259.82	4631.94	3791.00
		PIII(D180)	13	3169.54	2095.85	2238.00
	HIV	PRE	14	2407.07	1943.74	2006.50
		PIII(D7)	13	5926.00	3547.07	5515.00
		PIII(D14)	13	5932.08	3971.76	5651.00
		PIII(D30)	13	4642.62	1946.93	4138.00
	HIV-CQ	PIII(D180)	14	3553.93	2107.94	2856.50
		PRE	13	2031.38	1156.46	2000.00
	HIV-CQ	PIII(D7)	12	5992.92	4169.49	4390.00
		PIII(D14)	13	7883.92	8706.68	5272.00
		PIII(D30)	11	4902.73	5053.05	4407.00
		PIII(D180)	13	3389.54	2266.44	2530.00
	HIV	PRE	14	2583.43	2032.31	1974.50
		PIII(D7)	13	6570.92	3986.34	6613.00
		PIII(D14)	13	6510.31	4151.72	6035.00
		PIII(D30)	13	5035.15	2126.27	4589.00
		PIII(D180)	14	3739.57	2092.03	3079.00

N = number of subjects with available results

SD = Standard Deviation

POOL_F4CO = Frequency of CD4⁺ T-cells expressing cytokines after in vitro stimulation with a peptide pool covering the complete sequence of the F4co fusion antigen.

F4CO_EST = Frequency of CD4⁺ T-cells expressing cytokines in response to the F4co fusion protein (all antigens) was estimated by adding individual frequencies of CD4⁺ T-cells to each of the 4 antigens (RT, Nef, p17, p24)

PRE = Pre Dose 3, i.e. Pre-Booster Dose

PIII(D7) = Day 7 Post Dose 3

PIII(D14) = Day 14 Post Dose 3

PIII(D30) = Day 30 Post Dose 3

PIII(D180) = Day 180 Post Dose 3

Secondary Outcome Variable(s): Cytokine/marker co-expression profile of the F4 vaccine- and each antigen-specific CD4+ T cells (ATP cohort for immunogenicity)

Stimulating Ag	Expressed Marker	Group	Activity	N	Mean	SD	Median
RT	CD40L+	HIV-CQ	PRE	13	251.00	338.31	163.00
			PIII(D7)	12	1489.25	1270.12	1080.50
			PIII(D14)	13	979.15	1285.48	522.00
			PIII(D30)	11	497.91	478.68	262.00
			PIII(D180)	13	237.08	123.44	229.00
		HIV	PRE	14	198.21	194.18	184.00
			PIII(D7)	13	1161.77	768.65	1209.00
			PIII(D14)	13	712.54	687.94	748.00
			PIII(D30)	13	397.77	285.94	309.00
			PIII(D180)	14	283.43	160.25	249.00
	IL2+	HIV-CQ	PRE	13	19.46	31.33	1.00
			PIII(D7)	12	105.17	75.67	85.50
			PIII(D14)	13	83.69	63.10	97.00
			PIII(D30)	11	34.09	36.22	24.00
			PIII(D180)	13	72.54	91.75	41.00
		HIV	PRE	14	39.57	45.22	15.00
			PIII(D7)	13	70.08	86.06	42.00
			PIII(D14)	13	77.31	99.10	35.00
			PIII(D30)	13	52.62	44.60	36.00
			PIII(D180)	14	85.64	81.38	74.00
	TNF+	HIV-CQ	PRE	13	89.23	115.17	18.00
			PIII(D7)	12	382.17	309.11	421.00
			PIII(D14)	13	234.38	200.60	228.00
			PIII(D30)	11	112.45	97.44	124.00
			PIII(D180)	13	59.38	53.23	74.00
		HIV	PRE	14	143.93	160.43	61.50
			PIII(D7)	13	451.77	486.29	312.00
			PIII(D14)	13	374.69	338.63	318.00
			PIII(D30)	13	226.92	203.57	231.00
			PIII(D180)	14	38.14	60.39	7.00
	IFN+	HIV-CQ	PRE	13	15.08	18.76	7.00
			PIII(D7)	12	88.92	66.80	91.50
			PIII(D14)	13	36.31	67.55	9.00
			PIII(D30)	11	13.09	16.39	1.00
			PIII(D180)	13	27.46	37.51	13.00
		HIV	PRE	14	14.50	19.04	13.00
			PIII(D7)	13	52.46	49.68	56.00
			PIII(D14)	13	38.69	53.68	16.00
			PIII(D30)	13	11.15	13.70	1.00
			PIII(D180)	14	21.71	24.41	12.50
	CD40L+IL2+	HIV-CQ	PRE	13	380.31	274.90	377.00
			PIII(D7)	12	1351.08	1122.32	924.00
			PIII(D14)	13	1432.92	1656.64	922.00
			PIII(D30)	11	809.09	919.18	615.00
			PIII(D180)	13	780.46	502.48	558.00
		HIV	PRE	14	412.79	390.22	315.00
			PIII(D7)	13	1409.46	1096.10	1424.00

			PIII(D14)	13	1114.69	961.19	990.00
			PIII(D30)	13	830.08	367.95	828.00
			PIII(D180)	14	763.57	429.12	797.50
	CD40L+TNF+	HIV-CQ	PRE	13	42.00	38.98	41.00
			PIII(D7)	12	284.25	213.29	237.00
			PIII(D14)	13	307.46	265.82	300.00
			PIII(D30)	11	188.09	150.18	204.00
			PIII(D180)	13	55.00	44.42	54.00
		HIV	PRE	14	61.00	59.37	36.50
			PIII(D7)	13	332.38	288.86	315.00
			PIII(D14)	13	391.62	354.72	291.00
			PIII(D30)	13	184.31	122.12	137.00
			PIII(D180)	14	50.86	45.93	40.50
	CD40L+IFN+	HIV-CQ	PRE	13	4.62	6.09	1.00
			PIII(D7)	12	107.75	112.03	69.00
			PIII(D14)	13	82.08	135.52	27.00
			PIII(D30)	11	22.91	29.45	14.00
			PIII(D180)	13	6.38	9.54	1.00
		HIV	PRE	14	4.29	8.58	1.00
			PIII(D7)	13	78.15	73.43	84.00
			PIII(D14)	13	49.38	55.16	28.00
			PIII(D30)	13	26.85	21.20	15.00
			PIII(D180)	14	15.57	20.59	14.00
	IL2+TNF+	HIV-CQ	PRE	13	33.46	43.23	14.00
			PIII(D7)	12	95.33	69.93	83.50
			PIII(D14)	13	96.38	119.22	53.00
			PIII(D30)	11	63.91	97.95	27.00
			PIII(D180)	13	46.00	45.89	26.00
		HIV	PRE	14	36.86	56.19	6.50
			PIII(D7)	13	75.85	129.27	37.00
			PIII(D14)	13	80.08	115.78	22.00
			PIII(D30)	13	96.54	114.52	55.00
			PIII(D180)	14	67.64	38.82	67.50
	IL2+IFN+	HIV-CQ	PRE	13	2.00	3.61	1.00
			PIII(D7)	12	11.25	11.97	10.50
			PIII(D14)	13	7.15	8.88	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	8.23	12.11	1.00
		HIV	PRE	14	4.79	10.98	1.00
			PIII(D7)	13	6.85	8.31	1.00
			PIII(D14)	13	9.46	13.24	1.00
			PIII(D30)	13	6.15	8.74	1.00
			PIII(D180)	14	6.79	8.52	1.00
	TNF+IFN+	HIV-CQ	PRE	13	2.08	3.88	1.00
			PIII(D7)	12	33.25	36.09	18.00
			PIII(D14)	13	37.69	49.98	23.00
			PIII(D30)	11	12.27	12.37	14.00
			PIII(D180)	13	14.46	26.78	1.00
		HIV	PRE	14	4.79	8.04	1.00
			PIII(D7)	13	35.38	49.28	28.00
			PIII(D14)	13	30.38	36.91	14.00
			PIII(D30)	13	25.31	27.49	19.00
			PIII(D180)	14	28.79	34.46	15.00
	CD40L+IL2+TNF+	HIV-CQ	PRE	13	493.85	385.99	475.00
			PIII(D7)	12	1245.25	793.13	842.00

			PIII(D14)	13	1796.23	1487.65	1606.00
			PIII(D30)	11	1222.36	1080.04	1209.00
			PIII(D180)	13	667.31	490.77	471.00
		HIV	PRE	14	739.07	655.84	474.50
			PIII(D7)	13	1745.38	1263.39	1575.00
			PIII(D14)	13	1794.23	1118.40	1901.00
			PIII(D30)	13	1430.00	699.66	1297.00
			PIII(D180)	14	883.71	578.59	709.50
	CD40L+IL2+IFN+	HIV-CQ	PRE	13	29.08	32.25	15.00
			PIII(D7)	12	186.25	210.81	89.50
			PIII(D14)	13	185.31	345.51	54.00
			PIII(D30)	11	98.18	176.93	30.00
			PIII(D180)	13	95.46	111.35	68.00
		HIV	PRE	14	23.93	32.73	12.50
			PIII(D7)	13	159.00	160.40	151.00
			PIII(D14)	13	109.31	119.81	84.00
			PIII(D30)	13	67.46	50.52	56.00
			PIII(D180)	14	59.64	64.89	40.50
	CD40L+TNF+IFN+	HIV-CQ	PRE	13	6.46	7.50	1.00
			PIII(D7)	12	59.92	51.56	43.00
			PIII(D14)	13	73.77	76.09	50.00
			PIII(D30)	11	38.36	39.67	27.00
			PIII(D180)	13	7.00	8.72	1.00
		HIV	PRE	14	6.43	9.58	1.00
			PIII(D7)	13	62.54	60.89	56.00
			PIII(D14)	13	64.08	87.54	28.00
			PIII(D30)	13	44.62	56.02	15.00
			PIII(D180)	14	17.29	25.47	1.00
	IL2+TNF+IFN+	HIV-CQ	PRE	13	4.62	6.09	1.00
			PIII(D7)	12	16.08	19.53	13.50
			PIII(D14)	13	11.69	16.50	8.00
			PIII(D30)	11	7.27	10.53	1.00
			PIII(D180)	13	15.69	23.67	1.00
		HIV	PRE	14	8.64	13.94	1.00
			PIII(D7)	13	18.85	16.53	14.00
			PIII(D14)	13	13.15	22.91	1.00
			PIII(D30)	13	9.31	8.77	13.00
			PIII(D180)	14	18.00	22.96	13.50
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	84.54	128.30	57.00
			PIII(D7)	12	323.50	306.14	206.50
			PIII(D14)	13	451.85	777.43	254.00
			PIII(D30)	11	314.91	449.87	136.00
			PIII(D180)	13	150.46	155.61	64.00
		HIV	PRE	14	82.07	87.47	48.00
			PIII(D7)	13	348.00	355.04	213.00
			PIII(D14)	13	352.54	309.12	285.00
			PIII(D30)	13	275.23	222.22	237.00
			PIII(D180)	14	155.43	159.30	87.50
Nef	CD40L+	HIV-CQ	PRE	13	183.23	237.79	113.00
			PIII(D7)	12	496.00	586.39	339.00
			PIII(D14)	13	374.46	356.24	224.00
			PIII(D30)	11	179.91	194.01	193.00
			PIII(D180)	13	139.00	135.62	107.00
		HIV	PRE	14	40.64	71.47	1.00
			PIII(D7)	13	361.69	323.25	294.00

			PIII(D14)	13	249.92	247.46	219.00
			PIII(D30)	13	145.31	137.13	153.00
			PIII(D180)	14	94.79	104.02	54.00
	IL2+	HIV-CQ	PRE	13	16.85	26.00	1.00
			PIII(D7)	12	44.08	56.22	29.50
			PIII(D14)	13	42.46	44.77	25.00
			PIII(D30)	11	30.36	40.60	1.00
			PIII(D180)	13	40.00	50.04	21.00
		HIV	PRE	14	55.64	97.63	4.00
			PIII(D7)	13	55.23	73.47	14.00
			PIII(D14)	13	49.23	71.08	14.00
			PIII(D30)	13	18.15	24.03	14.00
			PIII(D180)	14	27.36	33.12	14.00
	TNF+	HIV-CQ	PRE	13	54.23	129.79	1.00
			PIII(D7)	12	114.25	99.70	115.00
			PIII(D14)	13	85.23	103.20	28.00
			PIII(D30)	11	26.27	46.14	1.00
			PIII(D180)	13	20.31	33.89	1.00
		HIV	PRE	14	41.86	72.17	1.00
			PIII(D7)	13	180.00	215.14	97.00
			PIII(D14)	13	106.92	107.23	95.00
			PIII(D30)	13	76.54	115.51	10.00
			PIII(D180)	14	15.29	27.27	1.00
	IFN+	HIV-CQ	PRE	13	12.54	14.26	1.00
			PIII(D7)	12	27.92	50.40	14.00
			PIII(D14)	13	23.38	25.37	20.00
			PIII(D30)	11	4.64	12.06	1.00
			PIII(D180)	13	22.77	19.57	14.00
		HIV	PRE	14	3.43	6.37	1.00
			PIII(D7)	13	13.46	20.57	1.00
			PIII(D14)	13	17.23	28.03	1.00
			PIII(D30)	13	13.46	20.48	1.00
			PIII(D180)	14	19.71	21.26	14.00
	CD40L+IL2+	HIV-CQ	PRE	13	107.15	138.39	84.00
			PIII(D7)	12	463.42	853.26	199.00
			PIII(D14)	13	524.00	740.73	258.00
			PIII(D30)	11	248.36	364.96	97.00
			PIII(D180)	13	274.77	401.13	148.00
		HIV	PRE	14	102.36	111.75	57.00
			PIII(D7)	13	308.92	294.27	263.00
			PIII(D14)	13	276.77	315.06	191.00
			PIII(D30)	13	198.92	185.00	139.00
			PIII(D180)	14	168.29	144.75	129.50
	CD40L+TNF+	HIV-CQ	PRE	13	23.46	39.18	3.00
			PIII(D7)	12	106.08	103.13	102.50
			PIII(D14)	13	96.00	92.51	95.00
			PIII(D30)	11	52.91	45.24	56.00
			PIII(D180)	13	14.08	14.90	13.00
		HIV	PRE	14	11.93	12.42	6.50
			PIII(D7)	13	88.08	71.29	55.00
			PIII(D14)	13	87.62	101.86	56.00
			PIII(D30)	13	37.69	42.56	27.00
			PIII(D180)	14	12.79	16.36	1.00
	CD40L+IFN+	HIV-CQ	PRE	13	3.46	6.84	1.00
			PIII(D7)	12	32.92	66.28	14.00

			PIII(D14)	13	16.00	20.92	14.00
			PIII(D30)	11	7.00	9.62	1.00
			PIII(D180)	13	7.00	11.40	1.00
		HIV	PRE	14	2.64	4.22	1.00
			PIII(D7)	13	25.46	27.41	15.00
			PIII(D14)	13	15.31	19.85	1.00
			PIII(D30)	13	12.00	11.71	13.00
			PIII(D180)	14	4.71	6.09	1.00
	IL2+TNF+	HIV-CQ	PRE	13	27.23	44.22	9.00
			PIII(D7)	12	25.42	30.45	14.00
			PIII(D14)	13	45.23	49.22	28.00
			PIII(D30)	11	16.91	25.54	1.00
			PIII(D180)	13	12.38	16.92	1.00
		HIV	PRE	14	12.93	16.99	1.00
			PIII(D7)	13	32.69	57.90	6.00
			PIII(D14)	13	27.08	37.60	14.00
	IL2+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	3.33	5.47	1.00
			PIII(D14)	13	3.00	4.88	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	4.00	7.79	1.00
		HIV	PRE	14	1.93	3.47	1.00
			PIII(D7)	13	7.08	12.80	1.00
			PIII(D14)	13	5.85	14.73	1.00
	TNF+IFN+	HIV-CQ	PRE	13	3.69	6.82	1.00
			PIII(D7)	12	11.00	14.20	5.00
			PIII(D14)	13	14.46	18.32	4.00
			PIII(D30)	11	7.45	13.06	1.00
			PIII(D180)	13	8.00	13.74	1.00
		HIV	PRE	14	6.64	10.35	1.00
			PIII(D7)	13	13.15	15.25	6.00
			PIII(D14)	13	12.85	16.39	1.00
	CD40L+IL2+TNF+	HIV-CQ	PRE	13	156.69	148.08	97.00
			PIII(D7)	12	409.50	520.12	268.50
			PIII(D14)	13	582.23	596.67	480.00
			PIII(D30)	11	363.18	326.07	401.00
			PIII(D180)	13	201.46	247.37	118.00
		HIV	PRE	14	168.00	171.41	93.50
			PIII(D7)	13	373.00	386.24	333.00
			PIII(D14)	13	495.92	615.84	292.00
	CD40L+IL2+IFN+	HIV-CQ	PRE	13	10.00	16.96	1.00
			PIII(D7)	12	59.17	111.98	33.00
			PIII(D14)	13	52.54	91.43	8.00
			PIII(D30)	11	32.18	60.36	14.00
			PIII(D180)	13	29.00	37.52	14.00
		HIV	PRE	14	6.79	8.80	1.00
			PIII(D7)	13	45.77	60.54	15.00

			PIII(D14)	13	33.69	48.52	10.00
			PIII(D30)	13	25.46	19.27	25.00
			PIII(D180)	14	23.86	43.85	10.50
	CD40L+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	22.75	27.72	12.50
			PIII(D14)	13	20.85	27.29	14.00
			PIII(D30)	11	8.27	8.75	1.00
			PIII(D180)	13	3.00	4.88	1.00
		HIV	PRE	14	1.64	2.41	1.00
			PIII(D7)	13	20.62	19.35	14.00
			PIII(D14)	13	20.46	27.10	10.00
			PIII(D30)	13	8.00	11.43	1.00
			PIII(D180)	14	5.29	9.02	1.00
	IL2+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	4.83	8.30	1.00
			PIII(D14)	13	3.54	5.03	1.00
			PIII(D30)	11	2.18	3.92	1.00
			PIII(D180)	13	7.00	10.09	1.00
		HIV	PRE	14	2.71	4.43	1.00
			PIII(D7)	13	10.00	15.92	1.00
			PIII(D14)	13	6.85	9.62	1.00
			PIII(D30)	13	7.00	10.09	1.00
			PIII(D180)	14	5.64	8.23	1.00
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	33.46	58.42	14.00
			PIII(D7)	12	109.42	166.99	67.50
			PIII(D14)	13	110.46	189.89	29.00
			PIII(D30)	11	58.18	78.66	41.00
			PIII(D180)	13	38.00	54.11	26.00
		HIV	PRE	14	27.57	40.28	12.50
			PIII(D7)	13	117.00	139.95	80.00
			PIII(D14)	13	126.77	197.44	28.00
			PIII(D30)	13	81.46	119.70	38.00
			PIII(D180)	14	43.29	48.51	24.00
p17	CD40L+	HIV-CQ	PRE	13	91.00	159.26	1.00
			PIII(D7)	12	325.75	407.40	237.50
			PIII(D14)	13	333.00	651.76	112.00
			PIII(D30)	11	158.18	178.40	150.00
			PIII(D180)	13	69.23	74.10	28.00
		HIV	PRE	14	114.64	255.19	23.50
			PIII(D7)	13	237.62	197.80	217.00
			PIII(D14)	13	181.31	171.53	132.00
			PIII(D30)	13	118.15	119.73	82.00
			PIII(D180)	14	103.21	94.35	78.50
	IL2+	HIV-CQ	PRE	13	17.92	26.20	1.00
			PIII(D7)	12	28.75	35.41	28.00
			PIII(D14)	13	21.92	29.01	8.00
			PIII(D30)	11	3.45	8.14	1.00
			PIII(D180)	13	7.62	15.09	1.00
		HIV	PRE	14	28.79	41.83	1.00
			PIII(D7)	13	23.46	30.16	5.00
			PIII(D14)	13	26.62	55.31	1.00
			PIII(D30)	13	20.92	20.36	14.00
			PIII(D180)	14	14.71	26.37	1.00
	TNF+	HIV-CQ	PRE	13	66.15	109.56	1.00
			PIII(D7)	12	116.67	156.36	40.00

			PIII(D14)	13	67.85	57.86	67.00
			PIII(D30)	11	45.45	94.40	14.00
			PIII(D180)	13	24.08	35.56	1.00
		HIV	PRE	14	34.64	61.87	1.00
			PIII(D7)	13	341.15	667.38	68.00
			PIII(D14)	13	127.15	122.74	140.00
			PIII(D30)	13	165.54	199.74	82.00
			PIII(D180)	14	26.07	30.12	20.00
	IFN+	HIV-CQ	PRE	13	4.15	5.40	1.00
			PIII(D7)	12	9.50	12.61	1.00
			PIII(D14)	13	5.23	7.41	1.00
			PIII(D30)	11	10.09	24.20	1.00
			PIII(D180)	13	17.00	21.64	14.00
		HIV	PRE	14	10.43	14.41	1.00
			PIII(D7)	13	13.08	13.24	14.00
			PIII(D14)	13	13.92	14.42	9.00
	CD40L+IL2+	HIV-CQ	PIII(D30)	13	7.92	9.89	1.00
			PIII(D180)	14	10.50	16.34	1.00
		HIV	PRE	14	109.07	135.18	69.00
			PIII(D7)	13	268.69	243.88	165.00
			PIII(D14)	13	243.23	225.67	139.00
		HIV	PIII(D30)	13	160.31	156.71	110.00
			PIII(D180)	14	229.36	223.03	193.00
	CD40L+TNF+	HIV-CQ	PRE	13	48.62	61.54	27.00
			PIII(D7)	12	204.83	188.15	196.00
			PIII(D14)	13	364.23	781.77	112.00
			PIII(D30)	11	208.27	372.90	122.00
			PIII(D180)	13	187.08	281.25	138.00
		HIV	PRE	14	30.54	38.05	24.00
			PIII(D7)	12	69.92	70.00	41.00
			PIII(D14)	13	90.15	150.08	28.00
	CD40L+IFN+	HIV-CQ	PIII(D30)	11	57.82	53.11	41.00
			PIII(D180)	13	12.00	13.48	14.00
		HIV	PRE	14	21.21	41.20	1.00
			PIII(D7)	13	80.31	76.66	61.00
			PIII(D14)	13	71.77	78.00	41.00
		HIV	PIII(D30)	13	42.08	64.35	14.00
			PIII(D180)	14	11.64	17.59	1.00
	IL2+TNF+	HIV-CQ	PRE	13	4.08	11.09	1.00
			PIII(D7)	12	13.58	14.68	7.50
			PIII(D14)	13	23.77	52.09	8.00
			PIII(D30)	11	16.64	24.01	10.00
			PIII(D180)	13	5.69	6.96	1.00
		HIV	PRE	14	1.57	2.14	1.00
			PIII(D7)	13	18.08	17.08	14.00
			PIII(D14)	13	11.31	16.31	1.00
		HIV-CQ	PIII(D30)	13	11.77	14.60	1.00
			PIII(D180)	14	5.86	10.00	1.00
		HIV	PRE	14	12.29	21.51	1.00
			PIII(D7)	13	19.00	35.48	1.00

			PIII(D14)	13	49.62	110.84	1.00
			PIII(D30)	13	19.92	34.91	1.00
			PIII(D180)	14	11.14	14.34	1.00
	IL2+IFN+	HIV-CQ	PRE	13	2.00	3.61	1.00
			PIII(D7)	12	1.00	0.00	1.00
			PIII(D14)	13	4.62	8.12	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	5.08	8.29	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	2.15	2.82	1.00
			PIII(D14)	13	3.54	6.36	1.00
			PIII(D30)	13	2.23	4.44	1.00
			PIII(D180)	14	4.71	7.95	1.00
	TNF+IFN+	HIV-CQ	PRE	13	4.69	10.07	1.00
			PIII(D7)	12	13.25	19.80	7.00
			PIII(D14)	13	10.23	16.56	1.00
			PIII(D30)	11	6.45	8.66	1.00
			PIII(D180)	13	3.31	5.65	1.00
		HIV	PRE	14	1.93	3.47	1.00
			PIII(D7)	13	8.62	13.12	1.00
			PIII(D14)	13	8.69	14.50	1.00
			PIII(D30)	13	4.23	5.39	1.00
			PIII(D180)	14	4.07	6.17	1.00
	CD40L+IL2+TNF+	HIV-CQ	PRE	13	101.15	105.96	84.00
			PIII(D7)	12	234.17	266.87	194.00
			PIII(D14)	13	508.38	863.65	192.00
			PIII(D30)	11	456.73	595.11	204.00
			PIII(D180)	13	153.46	191.30	94.00
		HIV	PRE	14	180.57	173.31	115.00
			PIII(D7)	13	422.92	430.87	302.00
			PIII(D14)	13	490.77	588.28	314.00
			PIII(D30)	13	411.15	406.59	203.00
			PIII(D180)	14	279.00	249.03	239.50
	CD40L+IL2+IFN+	HIV-CQ	PRE	13	9.62	12.49	1.00
			PIII(D7)	12	29.58	27.70	27.50
			PIII(D14)	13	53.92	170.54	1.00
			PIII(D30)	11	30.09	68.34	10.00
			PIII(D180)	13	22.54	43.19	13.00
		HIV	PRE	14	10.21	15.04	1.00
			PIII(D7)	13	27.46	35.88	14.00
			PIII(D14)	13	25.54	44.65	1.00
			PIII(D30)	13	18.46	20.37	14.00
			PIII(D180)	14	25.57	36.72	13.00
	CD40L+TNF+IFN+	HIV-CQ	PRE	13	1.46	1.66	1.00
			PIII(D7)	12	10.25	11.34	5.00
			PIII(D14)	13	13.62	26.83	1.00
			PIII(D30)	11	6.45	12.93	1.00
			PIII(D180)	13	1.00	0.00	1.00
		HIV	PRE	14	6.36	9.83	1.00
			PIII(D7)	13	21.23	22.14	14.00
			PIII(D14)	13	11.92	12.07	11.00
			PIII(D30)	13	6.77	8.44	1.00
			PIII(D180)	14	7.79	16.02	1.00
	IL2+TNF+IFN+	HIV-CQ	PRE	13	1.00	0.00	1.00
			PIII(D7)	12	7.00	8.08	4.00

			PIII(D14)	13	3.00	4.10	1.00
			PIII(D30)	11	1.00	0.00	1.00
			PIII(D180)	13	7.23	8.80	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	5.00	8.53	1.00
			PIII(D14)	13	5.15	8.09	1.00
			PIII(D30)	13	3.38	4.70	1.00
			PIII(D180)	14	3.43	6.19	1.00
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	14.62	24.54	1.00
			PIII(D7)	12	66.25	77.90	34.50
			PIII(D14)	13	184.85	491.04	23.00
			PIII(D30)	11	117.64	278.17	40.00
			PIII(D180)	13	26.46	50.18	14.00
		HIV	PRE	14	21.36	36.43	1.00
			PIII(D7)	13	120.92	132.51	31.00
			PIII(D14)	13	133.77	218.56	42.00
			PIII(D30)	13	97.92	128.65	55.00
			PIII(D180)	14	68.07	99.68	17.50
p24	CD40L+	HIV-CQ	PRE	13	241.23	463.87	79.00
			PIII(D7)	12	664.33	893.66	452.00
			PIII(D14)	13	321.08	398.90	217.00
			PIII(D30)	11	196.36	243.32	86.00
			PIII(D180)	13	133.23	77.32	118.00
		HIV	PRE	14	208.50	361.45	70.00
			PIII(D7)	13	329.08	269.15	395.00
			PIII(D14)	13	215.92	205.21	154.00
			PIII(D30)	13	161.46	124.96	181.00
			PIII(D180)	14	170.64	156.25	165.00
	IL2+	HIV-CQ	PRE	13	27.46	44.68	1.00
			PIII(D7)	12	63.17	67.71	40.50
			PIII(D14)	13	39.62	62.15	14.00
			PIII(D30)	11	28.45	46.30	14.00
			PIII(D180)	13	51.00	52.05	35.00
		HIV	PRE	14	28.79	35.79	13.00
			PIII(D7)	13	33.69	41.39	24.00
			PIII(D14)	13	35.08	62.28	5.00
			PIII(D30)	13	47.38	47.91	41.00
			PIII(D180)	14	19.14	26.91	2.50
	TNF+	HIV-CQ	PRE	13	41.85	75.33	1.00
			PIII(D7)	12	115.67	132.01	69.00
			PIII(D14)	13	93.31	131.31	36.00
			PIII(D30)	11	45.18	56.21	1.00
			PIII(D180)	13	42.00	52.83	35.00
		HIV	PRE	14	35.29	53.43	6.00
			PIII(D7)	13	177.31	238.54	73.00
			PIII(D14)	13	131.62	154.23	53.00
			PIII(D30)	13	81.38	106.79	8.00
			PIII(D180)	14	12.43	22.95	1.00
	IFN+	HIV-CQ	PRE	13	10.77	17.63	1.00
			PIII(D7)	12	14.83	22.02	4.00
			PIII(D14)	13	6.31	8.19	1.00
			PIII(D30)	11	7.64	11.49	1.00
			PIII(D180)	13	34.69	43.23	14.00
		HIV	PRE	14	15.00	19.42	1.00
			PIII(D7)	13	21.69	18.45	14.00

			PIII(D14)	13	10.54	11.96	14.00
			PIII(D30)	13	8.92	12.91	1.00
			PIII(D180)	14	11.14	21.49	1.00
	CD40L+IL2+	HIV-CQ	PRE	13	167.92	115.68	176.00
			PIII(D7)	12	424.75	423.89	275.00
			PIII(D14)	13	443.38	567.82	244.00
			PIII(D30)	11	251.55	396.13	83.00
			PIII(D180)	13	294.77	230.12	234.00
		HIV	PRE	14	197.71	190.99	137.00
			PIII(D7)	13	353.54	288.87	230.00
			PIII(D14)	13	343.31	344.14	284.00
			PIII(D30)	13	259.38	220.79	189.00
			PIII(D180)	14	298.21	269.88	196.00
	CD40L+TNF+	HIV-CQ	PRE	13	22.92	27.04	14.00
			PIII(D7)	12	130.42	133.87	104.00
			PIII(D14)	13	146.15	154.69	86.00
			PIII(D30)	11	76.27	66.24	54.00
			PIII(D180)	13	18.31	23.39	1.00
		HIV	PRE	14	38.29	43.69	21.00
			PIII(D7)	13	98.62	76.28	99.00
			PIII(D14)	13	130.62	103.10	125.00
			PIII(D30)	13	58.00	68.11	42.00
			PIII(D180)	14	18.64	17.50	14.50
	CD40L+IFN+	HIV-CQ	PRE	13	2.46	3.84	1.00
			PIII(D7)	12	23.17	28.16	12.50
			PIII(D14)	13	17.46	19.46	11.00
			PIII(D30)	11	4.27	5.66	1.00
			PIII(D180)	13	3.00	4.88	1.00
		HIV	PRE	14	5.64	9.04	1.00
			PIII(D7)	13	9.46	16.75	1.00
			PIII(D14)	13	10.23	10.72	9.00
			PIII(D30)	13	8.77	10.29	1.00
			PIII(D180)	14	5.57	11.73	1.00
	IL2+TNF+	HIV-CQ	PRE	13	9.23	13.71	1.00
			PIII(D7)	12	30.75	31.89	16.50
			PIII(D14)	13	58.46	124.11	27.00
			PIII(D30)	11	25.45	39.68	1.00
			PIII(D180)	13	19.31	24.83	14.00
		HIV	PRE	14	24.50	36.16	1.00
			PIII(D7)	13	36.00	51.83	9.00
			PIII(D14)	13	45.46	69.26	22.00
			PIII(D30)	13	42.23	78.14	14.00
			PIII(D180)	14	36.36	40.93	27.00
	IL2+IFN+	HIV-CQ	PRE	13	2.46	3.84	1.00
			PIII(D7)	12	9.75	14.19	1.00
			PIII(D14)	13	2.62	4.35	1.00
			PIII(D30)	11	2.91	4.39	1.00
			PIII(D180)	13	3.15	5.27	1.00
		HIV	PRE	14	1.00	0.00	1.00
			PIII(D7)	13	1.00	0.00	1.00
			PIII(D14)	13	1.77	2.77	1.00
			PIII(D30)	13	4.00	7.79	1.00
			PIII(D180)	14	2.93	4.91	1.00
	TNF+IFN+	HIV-CQ	PRE	13	8.08	8.89	1.00
			PIII(D7)	12	14.42	16.80	7.50

			PIII(D14)	13	15.00	26.73	1.00
			PIII(D30)	11	11.55	13.69	1.00
			PIII(D180)	13	7.54	9.73	1.00
		HIV	PRE	14	3.57	7.25	1.00
			PIII(D7)	13	19.85	22.93	12.00
			PIII(D14)	13	12.08	18.33	1.00
			PIII(D30)	13	20.00	22.91	14.00
			PIII(D180)	14	11.36	15.34	1.00
	CD40L+IL2+TNF+	HIV-CQ	PRE	13	245.92	155.04	267.00
			PIII(D7)	12	482.42	370.26	389.50
			PIII(D14)	13	737.23	672.45	569.00
			PIII(D30)	11	438.45	407.77	516.00
			PIII(D180)	13	240.54	142.12	233.00
		HIV	PRE	14	337.93	459.29	135.50
			PIII(D7)	13	533.54	453.87	410.00
			PIII(D14)	13	602.38	417.04	456.00
			PIII(D30)	13	552.85	509.80	379.00
			PIII(D180)	14	297.36	254.38	229.50
	CD40L+IL2+IFN+	HIV-CQ	PRE	13	9.85	14.01	1.00
			PIII(D7)	12	39.50	54.79	20.50
			PIII(D14)	13	47.85	83.09	11.00
			PIII(D30)	11	23.18	51.13	1.00
			PIII(D180)	13	25.00	31.16	18.00
		HIV	PRE	14	14.50	15.76	9.50
			PIII(D7)	13	26.38	31.00	14.00
			PIII(D14)	13	20.54	15.03	23.00
			PIII(D30)	13	28.15	33.03	15.00
			PIII(D180)	14	25.93	42.47	14.00
	CD40L+TNF+IFN+	HIV-CQ	PRE	13	2.46	3.84	1.00
			PIII(D7)	12	17.17	18.98	12.50
			PIII(D14)	13	21.54	30.13	14.00
			PIII(D30)	11	9.64	13.27	1.00
			PIII(D180)	13	4.15	6.01	1.00
		HIV	PRE	14	3.00	7.48	1.00
			PIII(D7)	13	17.23	20.10	14.00
			PIII(D14)	13	16.62	14.47	14.00
			PIII(D30)	13	5.85	6.45	1.00
			PIII(D180)	14	5.21	8.70	1.00
	IL2+TNF+IFN+	HIV-CQ	PRE	13	2.62	4.07	1.00
			PIII(D7)	12	7.17	15.94	1.00
			PIII(D14)	13	6.54	11.22	1.00
			PIII(D30)	11	7.91	20.40	1.00
			PIII(D180)	13	14.46	19.31	1.00
		HIV	PRE	14	3.86	5.68	1.00
			PIII(D7)	13	4.38	6.01	1.00
			PIII(D14)	13	6.15	12.86	1.00
			PIII(D30)	13	7.08	8.18	1.00
			PIII(D180)	14	9.79	19.58	1.00
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	32.00	45.15	1.00
			PIII(D7)	12	126.08	101.60	140.50
			PIII(D14)	13	152.08	235.21	66.00
			PIII(D30)	11	88.00	156.33	40.00
			PIII(D180)	13	43.46	40.80	43.00
		HIV	PRE	14	38.00	43.63	14.50
			PIII(D7)	13	92.08	100.28	70.00

POOL_F4CO			PIII(D14)	13	92.69	79.11	81.00
			PIII(D30)	13	81.08	98.42	57.00
			PIII(D180)	14	43.00	54.69	22.50
	CD40L+	HIV-CQ	PRE	13	219.69	242.15	177.00
			PIII(D7)	12	2569.42	2378.04	1809.50
			PIII(D14)	13	2077.08	2473.52	1015.00
			PIII(D30)	11	790.36	861.56	653.00
			PIII(D180)	13	540.77	273.82	497.00
		HIV	PRE	14	316.79	317.45	264.50
			PIII(D7)	13	2024.46	1425.22	2215.00
			PIII(D14)	13	1414.77	1495.08	1175.00
			PIII(D30)	13	718.00	421.85	650.00
			PIII(D180)	14	510.07	293.26	429.00
	IL2+	HIV-CQ	PRE	13	54.31	59.10	41.00
			PIII(D7)	12	155.25	104.26	141.50
			PIII(D14)	13	135.00	153.87	100.00
			PIII(D30)	11	80.00	81.29	55.00
			PIII(D180)	13	88.23	117.60	32.00
		HIV	PRE	14	68.36	66.69	57.00
			PIII(D7)	13	127.54	155.69	81.00
			PIII(D14)	13	112.85	112.53	92.00
			PIII(D30)	13	97.08	81.08	97.00
			PIII(D180)	14	75.29	66.40	58.50
	TNF+	HIV-CQ	PRE	13	168.38	257.64	20.00
			PIII(D7)	12	670.42	526.70	547.50
			PIII(D14)	13	594.77	271.64	612.00
			PIII(D30)	11	316.36	308.18	225.00
			PIII(D180)	13	116.23	70.76	126.00
		HIV	PRE	14	354.79	382.83	242.50
			PIII(D7)	13	852.15	710.98	625.00
			PIII(D14)	13	797.00	579.84	610.00
			PIII(D30)	13	458.00	312.15	445.00
			PIII(D180)	14	79.86	86.27	56.50
	IFN+	HIV-CQ	PRE	13	19.00	22.45	7.00
			PIII(D7)	12	147.17	128.73	110.00
			PIII(D14)	13	79.00	118.13	32.00
			PIII(D30)	11	22.18	31.73	14.00
			PIII(D180)	13	42.62	41.48	35.00
		HIV	PRE	14	14.50	24.67	1.00
			PIII(D7)	13	94.85	78.55	98.00
			PIII(D14)	13	73.69	68.47	47.00
			PIII(D30)	13	41.92	38.39	38.00
			PIII(D180)	14	41.21	44.30	38.50
	CD40L+IL2+	HIV-CQ	PRE	13	530.38	428.99	469.00
			PIII(D7)	12	2214.42	1897.86	1542.50
			PIII(D14)	13	2612.08	3285.70	1423.00
			PIII(D30)	11	1357.09	1671.93	964.00
			PIII(D180)	13	1387.00	1063.52	961.00
		HIV	PRE	14	761.21	779.83	568.50
			PIII(D7)	13	2313.00	1462.65	2199.00
			PIII(D14)	13	2054.69	1654.00	2037.00
			PIII(D30)	13	1379.46	465.53	1277.00
			PIII(D180)	14	1467.14	766.12	1351.50
	CD40L+TNF+	HIV-CQ	PRE	13	110.38	87.51	102.00
			PIII(D7)	12	498.83	283.09	514.50

			PIII(D14)	13	697.77	611.82	706.00
			PIII(D30)	11	349.45	278.88	399.00
			PIII(D180)	13	102.46	77.67	81.00
		HIV	PRE	14	127.21	117.19	69.50
			PIII(D7)	13	612.46	429.37	575.00
			PIII(D14)	13	674.69	644.10	498.00
			PIII(D30)	13	389.08	264.18	291.00
			PIII(D180)	14	126.07	136.35	74.00
	CD40L+IFN+	HIV-CQ	PRE	13	5.46	8.12	1.00
			PIII(D7)	12	166.75	182.67	82.50
			PIII(D14)	13	144.31	311.28	59.00
			PIII(D30)	11	47.36	77.00	21.00
			PIII(D180)	13	17.62	16.64	14.00
		HIV	PRE	14	6.79	9.28	1.00
			PIII(D7)	13	110.62	88.46	112.00
			PIII(D14)	13	99.77	114.18	56.00
			PIII(D30)	13	52.23	43.21	41.00
			PIII(D180)	14	27.50	22.28	27.00
	IL2+TNF+	HIV-CQ	PRE	13	57.92	57.54	55.00
			PIII(D7)	12	174.50	145.78	160.00
			PIII(D14)	13	157.38	189.19	122.00
			PIII(D30)	11	81.55	120.02	25.00
			PIII(D180)	13	66.92	78.59	26.00
		HIV	PRE	14	89.21	92.07	56.00
			PIII(D7)	13	130.77	148.93	93.00
			PIII(D14)	13	158.46	154.25	83.00
			PIII(D30)	13	172.38	172.83	109.00
			PIII(D180)	14	78.21	63.52	59.50
	IL2+IFN+	HIV-CQ	PRE	13	8.54	13.06	1.00
			PIII(D7)	12	18.42	25.40	6.00
			PIII(D14)	13	7.31	7.84	1.00
			PIII(D30)	11	8.00	16.27	1.00
			PIII(D180)	13	12.31	13.09	14.00
		HIV	PRE	14	2.57	4.07	1.00
			PIII(D7)	13	17.31	27.37	1.00
			PIII(D14)	13	14.92	23.98	1.00
			PIII(D30)	13	9.31	8.38	11.00
			PIII(D180)	14	15.57	14.15	14.00
	TNF+IFN+	HIV-CQ	PRE	13	11.38	12.86	1.00
			PIII(D7)	12	72.00	70.93	38.00
			PIII(D14)	13	74.85	101.05	51.00
			PIII(D30)	11	37.09	40.10	27.00
			PIII(D180)	13	29.54	37.57	19.00
		HIV	PRE	14	13.86	16.89	1.00
			PIII(D7)	13	70.92	48.55	56.00
			PIII(D14)	13	72.85	53.25	83.00
			PIII(D30)	13	71.23	47.07	75.00
			PIII(D180)	14	33.57	36.94	28.00
	CD40L+IL2+TNF+	HIV-CQ	PRE	13	898.77	623.76	792.00
			PIII(D7)	12	1923.25	1277.30	1430.00
			PIII(D14)	13	3026.38	2741.00	2032.00
			PIII(D30)	11	2101.18	1938.49	2243.00
			PIII(D180)	13	1223.69	639.64	1146.00
		HIV	PRE	14	1317.36	1116.41	836.00
			PIII(D7)	13	2612.62	1533.40	2764.00

			PIII(D14)	13	2837.92	1805.02	2804.00
			PIII(D30)	13	2438.31	1282.30	2137.00
			PIII(D180)	14	1504.71	971.92	1246.00
	CD40L+IL2+IFN+	HIV-CQ	PRE	13	43.54	46.86	28.00
			PIII(D7)	12	303.08	346.39	140.00
			PIII(D14)	13	328.62	667.97	96.00
			PIII(D30)	11	154.45	266.40	24.00
			PIII(D180)	13	163.62	180.19	116.00
		HIV	PRE	14	47.00	55.87	30.50
			PIII(D7)	13	238.46	216.12	204.00
			PIII(D14)	13	203.69	192.30	151.00
			PIII(D30)	13	116.77	75.39	109.00
			PIII(D180)	14	129.50	144.48	60.50
	CD40L+TNF+IFN+	HIV-CQ	PRE	13	4.62	8.26	1.00
			PIII(D7)	12	102.50	101.30	70.00
			PIII(D14)	13	123.54	177.39	74.00
			PIII(D30)	11	75.55	83.89	55.00
			PIII(D180)	13	28.38	20.61	27.00
		HIV	PRE	14	10.36	17.24	1.00
			PIII(D7)	13	98.00	99.01	97.00
			PIII(D14)	13	133.92	145.65	85.00
			PIII(D30)	13	96.08	79.32	82.00
			PIII(D180)	14	31.43	26.73	27.00
	IL2+TNF+IFN+	HIV-CQ	PRE	13	23.77	52.98	1.00
			PIII(D7)	12	33.25	31.64	18.50
			PIII(D14)	13	18.00	28.40	8.00
			PIII(D30)	11	16.64	28.37	1.00
			PIII(D180)	13	12.38	16.50	13.00
		HIV	PRE	14	12.21	15.43	11.00
			PIII(D7)	13	24.77	27.33	14.00
			PIII(D14)	13	29.92	36.48	14.00
			PIII(D30)	13	26.15	35.35	17.00
			PIII(D180)	14	40.64	73.33	17.50
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	140.46	151.64	95.00
			PIII(D7)	12	482.92	457.97	285.50
			PIII(D14)	13	806.23	1383.75	337.00
			PIII(D30)	11	540.91	978.59	244.00
			PIII(D180)	13	303.62	310.06	163.00
		HIV	PRE	14	177.50	198.45	147.00
			PIII(D7)	13	589.08	444.47	484.00
			PIII(D14)	13	632.46	526.28	639.00
			PIII(D30)	13	500.23	356.40	413.00
			PIII(D180)	14	318.14	289.80	216.00
F4CO_EST	CD40L+	HIV-CQ	PRE	13	766.46	1059.91	562.00
			PIII(D7)	12	2975.33	2547.01	2050.50
			PIII(D14)	13	2007.69	2571.73	1106.00
			PIII(D30)	11	1032.36	1013.43	584.00
			PIII(D180)	13	578.54	292.16	543.00
		HIV	PRE	14	562.00	597.16	270.50
			PIII(D7)	13	2090.15	1294.47	2296.00
			PIII(D14)	13	1359.69	1107.90	1108.00
			PIII(D30)	13	822.69	508.88	697.00
			PIII(D180)	14	652.07	422.72	507.00
	IL2+	HIV-CQ	PRE	13	81.69	86.10	54.00
			PIII(D7)	12	241.17	159.88	201.50

			PIII(D14)	13	187.69	163.12	130.00
			PIII(D30)	11	96.36	90.61	75.00
			PIII(D180)	13	171.15	169.27	82.00
		HIV	PRE	14	152.79	147.46	138.00
			PIII(D7)	13	182.46	202.23	165.00
			PIII(D14)	13	188.23	259.27	92.00
			PIII(D30)	13	139.08	98.15	134.00
			PIII(D180)	14	146.86	134.69	93.00
	TNF+	HIV-CQ	PRE	13	251.46	308.36	192.00
			PIII(D7)	12	728.75	500.51	844.00
			PIII(D14)	13	480.77	371.42	388.00
			PIII(D30)	11	229.36	193.36	194.00
			PIII(D180)	13	145.77	101.79	191.00
		HIV	PRE	14	255.71	275.62	129.50
			PIII(D7)	13	1150.23	1362.38	635.00
			PIII(D14)	13	740.38	619.92	477.00
			PIII(D30)	13	550.38	436.49	608.00
			PIII(D180)	14	91.93	114.52	40.50
	IFN+	HIV-CQ	PRE	13	42.54	31.52	43.00
			PIII(D7)	12	141.17	108.33	141.50
			PIII(D14)	13	71.23	85.05	30.00
			PIII(D30)	11	35.45	39.29	24.00
			PIII(D180)	13	101.92	60.84	120.00
		HIV	PRE	14	43.36	35.36	42.00
			PIII(D7)	13	100.69	75.06	93.00
			PIII(D14)	13	80.38	72.95	71.00
			PIII(D30)	13	41.46	35.69	30.00
			PIII(D180)	14	63.07	64.64	36.50
	CD40L+IL2+	HIV-CQ	PRE	13	704.00	445.63	659.00
			PIII(D7)	12	2444.08	2001.96	2048.00
			PIII(D14)	13	2764.54	3354.18	1724.00
			PIII(D30)	11	1517.27	1896.87	1042.00
			PIII(D180)	13	1537.08	1067.05	1184.00
		HIV	PRE	14	821.93	689.83	761.50
			PIII(D7)	13	2340.62	1484.36	2496.00
			PIII(D14)	13	1978.00	1463.45	1860.00
			PIII(D30)	13	1448.69	528.55	1217.00
			PIII(D180)	14	1459.43	782.57	1309.50
	CD40L+TNF+	HIV-CQ	PRE	13	118.92	85.95	74.00
			PIII(D7)	12	590.67	415.84	491.50
			PIII(D14)	13	639.77	597.92	554.00
			PIII(D30)	11	375.09	281.09	382.00
			PIII(D180)	13	99.38	58.53	109.00
		HIV	PRE	14	132.43	117.21	95.00
			PIII(D7)	13	599.38	439.16	591.00
			PIII(D14)	13	681.62	555.42	596.00
			PIII(D30)	13	322.08	248.69	234.00
			PIII(D180)	14	93.93	76.34	63.50
	CD40L+IFN+	HIV-CQ	PRE	13	14.62	18.90	4.00
			PIII(D7)	12	177.42	180.87	123.50
			PIII(D14)	13	139.31	207.06	68.00
			PIII(D30)	11	50.82	60.64	24.00
			PIII(D180)	13	22.08	20.15	17.00
		HIV	PRE	14	14.14	12.61	9.00
			PIII(D7)	13	131.15	95.80	127.00

			PIII(D14)	13	86.23	81.36	60.00
			PIII(D30)	13	59.38	31.06	61.00
			PIII(D180)	14	31.71	23.71	30.00
	IL2+TNF+	HIV-CQ	PRE	13	89.92	111.47	37.00
			PIII(D7)	12	177.33	128.48	165.00
			PIII(D14)	13	214.31	284.65	103.00
			PIII(D30)	11	118.09	173.14	30.00
			PIII(D180)	13	94.46	99.62	43.00
		HIV	PRE	14	86.57	98.33	34.50
			PIII(D7)	13	163.54	259.60	86.00
			PIII(D14)	13	202.23	301.19	49.00
			PIII(D30)	13	183.31	254.87	82.00
			PIII(D180)	14	127.50	84.09	87.50
	IL2+IFN+	HIV-CQ	PRE	13	7.46	7.77	4.00
			PIII(D7)	12	25.33	25.51	17.00
			PIII(D14)	13	17.38	16.94	10.00
			PIII(D30)	11	5.91	4.39	4.00
			PIII(D180)	13	20.46	22.57	4.00
		HIV	PRE	14	8.71	14.32	4.00
			PIII(D7)	13	17.08	18.20	12.00
			PIII(D14)	13	20.62	31.47	4.00
			PIII(D30)	13	13.38	12.57	4.00
			PIII(D180)	14	20.07	16.37	17.00
	TNF+IFN+	HIV-CQ	PRE	13	18.54	15.30	17.00
			PIII(D7)	12	71.92	56.30	45.00
			PIII(D14)	13	77.38	90.65	56.00
			PIII(D30)	11	37.73	23.30	35.00
			PIII(D180)	13	33.31	49.86	17.00
		HIV	PRE	14	16.93	17.95	14.00
			PIII(D7)	13	77.00	66.30	72.00
			PIII(D14)	13	64.00	52.60	64.00
			PIII(D30)	13	72.15	43.77	86.00
			PIII(D180)	14	62.00	50.60	59.50
	CD40L+IL2+TNF+	HIV-CQ	PRE	13	997.62	647.16	1050.00
			PIII(D7)	12	2371.33	1646.93	1587.00
			PIII(D14)	13	3624.08	3326.97	2652.00
			PIII(D30)	11	2480.73	2173.54	2635.00
			PIII(D180)	13	1262.77	866.92	1088.00
		HIV	PRE	14	1425.57	1220.37	972.50
			PIII(D7)	13	3074.85	1869.40	3392.00
			PIII(D14)	13	3383.31	2035.97	3279.00
			PIII(D30)	13	2687.77	1281.88	2593.00
			PIII(D180)	14	1650.93	983.53	1288.50
	CD40L+IL2+IFN+	HIV-CQ	PRE	13	58.54	52.38	51.00
			PIII(D7)	12	314.50	334.25	158.50
			PIII(D14)	13	339.62	628.29	107.00
			PIII(D30)	11	183.64	350.00	46.00
			PIII(D180)	13	172.00	181.17	123.00
		HIV	PRE	14	55.43	44.77	45.00
			PIII(D7)	13	258.62	202.74	254.00
			PIII(D14)	13	189.08	179.25	157.00
			PIII(D30)	13	139.54	72.42	139.00
			PIII(D180)	14	135.00	142.35	104.00
	CD40L+TNF+IFN+	HIV-CQ	PRE	13	11.38	9.53	4.00
			PIII(D7)	12	110.08	76.51	86.50

			PIII(D14)	13	129.77	144.26	82.00
			PIII(D30)	11	62.73	61.16	43.00
			PIII(D180)	13	15.15	13.04	16.00
		HIV	PRE	14	17.43	19.55	8.50
			PIII(D7)	13	121.62	87.03	111.00
			PIII(D14)	13	113.08	116.13	85.00
			PIII(D30)	13	65.23	61.53	44.00
			PIII(D180)	14	35.57	39.46	22.50
	IL2+TNF+IFN+	HIV-CQ	PRE	13	9.23	7.98	4.00
			PIII(D7)	12	35.08	43.07	21.00
			PIII(D14)	13	24.77	25.97	17.00
			PIII(D30)	11	18.36	32.05	4.00
			PIII(D180)	13	44.38	40.06	25.00
		HIV	PRE	14	16.21	19.06	4.00
			PIII(D7)	13	38.23	35.38	30.00
			PIII(D14)	13	31.31	35.56	17.00
			PIII(D30)	13	26.77	18.38	27.00
			PIII(D180)	14	36.86	43.67	30.00
	CD40L+IL2+TNF+IFN+	HIV-CQ	PRE	13	164.62	211.55	107.00
			PIII(D7)	12	625.25	545.52	348.00
			PIII(D14)	13	899.23	1640.96	457.00
			PIII(D30)	11	578.73	945.50	284.00
			PIII(D180)	13	258.38	267.86	134.00
		HIV	PRE	14	169.00	160.96	138.00
			PIII(D7)	13	678.00	548.73	512.00
			PIII(D14)	13	705.77	600.73	601.00
			PIII(D30)	13	535.69	406.61	384.00
			PIII(D180)	14	309.79	272.06	244.00

N = number of subjects with available results

SD = Standard Deviation

POOL_F4CO = Frequency of CD4+ T-cells expressing cytokines after in vitro stimulation with a peptide pool covering the complete sequence of the F4co fusion antigen.

F4CO_EST = Frequency of CD4+ T-cells expressing cytokines in response to the F4co fusion protein (all antigens) was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (RT, Nef, p17, p24)

PRE = Pre Dose 3, i.e. Pre-Booster Dose

PIII(D7) = Day 7 Post Dose 3

PIII(D14) = Day 14 Post Dose 3

PIII(D30) = Day 30 Post Dose 3

PIII(D180) = Day 180 Post Dose 3

Secondary Outcome Variable(s): Seropositivity rates and GMCs for HIV.p17 Ab.IgG antibodies (ATP cohort for immunogenicity)

				≥ 187 mEL.U/mL				GMC(mEL.U/mL)		
						95% CI		value	95% CI	
Antibody	Group	Timing	N	n	%	LL	UL		LL	UL
HIV.p17 Ab.IgG	HIV-CQ	PRE	13	0	0.0	0.0	24.7	93.5	93.5	93.5
		PREIII	13	0	0.0	0.0	24.7	93.5	93.5	93.5
		PIII(D7)	13	12	92.3	64.0	99.8	1599.4	704.7	3629.7
		PIII(D14)	13	13	100	75.3	100	5069.8	2356.8	10906.1
		PIII(D30)	13	13	100	75.3	100	5148.5	2493.1	10632.1
		PIII(D180)	13	13	100	75.3	100	1115.5	498.9	2493.9
	HIV	PRE	14	0	0.0	0.0	23.2	93.5	93.5	93.5
		PREIII	14	1	7.1	0.2	33.9	98.9	87.6	111.6
		PIII(D7)	14	11	78.6	49.2	95.3	1121.5	390.5	3220.5
		PIII(D14)	14	11	78.6	49.2	95.3	1763.3	545.6	5699.3
		PIII(D30)	14	10	71.4	41.9	91.6	1610.1	436.1	5944.5
		PIII(D180)	14	8	57.1	28.9	82.3	639.0	215.1	1899.0

PIII(D180) = Day 180 Post Dose 3

				≥119 mEL.U/mL				GMC(mEL.U/mL)		
						95% CI			95% CI	
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
HIV.p24 Ab.IgG	HIV-CQ	PRE	13	0	0.0	0.0	24.7	59.5	59.5	59.5
		PREIII	13	13	100	75.3	100	377.4	271.1	525.3
		PIII(D7)	13	13	100	75.3	100	31533.9	14691.0	67686.9
		PIII(D14)	13	13	100	75.3	100	78313.7	51412.0	119292.0
		PIII(D30)	13	13	100	75.3	100	61372.0	41678.5	90370.9
		PIII(D180)	13	13	100	75.3	100	27590.9	18812.2	40466.2
	HIV	PRE	14	0	0.0	0.0	23.2	59.5	59.5	59.5
		PREIII	14	12	85.7	57.2	98.2	483.3	222.0	1051.9
		PIII(D7)	14	14	100	76.8	100	36200.9	22284.8	58807.3
		PIII(D14)	14	14	100	76.8	100	59655.5	40848.9	87120.6
		PIII(D30)	14	14	100	76.8	100	49619.3	31879.0	77231.9
		PIII(D180)	14	14	100	76.8	100	27545.3	16128.6	47043.3

PIII(D180) = Day 180 Post Dose 3

				≥ 232 mEL.U/mL				GMC(mEL.U/mL)		
						95% CI			95% CI	
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
HIV.Nef Ab.IgG	HIV-CQ	PRE	13	0	0.0	0.0	24.7	116.0	116.0	116.0
		PREIII	13	10	76.9	46.2	95.0	394.6	243.4	639.5
		PIII(D7)	13	13	100	75.3	100	38430.3	15157.6	97435.4
		PIII(D14)	13	13	100	75.3	100	113387.2	62469.0	205808.7
		PIII(D30)	13	13	100	75.3	100	77192.3	39847.3	149537.1
		PIII(D180)	13	13	100	75.3	100	25141.1	14744.0	42870.2
	HIV	PRE	14	0	0.0	0.0	23.2	116.0	116.0	116.0
		PREIII	14	11	78.6	49.2	95.3	536.3	251.9	1141.7
		PIII(D7)	14	14	100	76.8	100	38621.8	19829.5	75223.5
		PIII(D14)	14	14	100	76.8	100	63283.3	36141.0	110809.8
		PIII(D30)	14	14	100	76.8	100	42709.2	21389.9	85277.2
		PIII(D180)	14	14	100	76.8	100	21371.8	10260.3	44517.0

N = number of subjects with available results

PIII(D180) = Day 180 Post Dose 3

				≥ 125 mEL.U/mL				GMC(mEL.U/mL)		
						95% CI				95% CI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
HIV.RT Ab.IgG	HIV-CQ	PRE	13	1	7.7	0.2	36.0	68.0	56.6	81.7
		PREIII	13	8	61.5	31.6	86.1	154.0	95.8	247.5
		PIII(D7)	13	13	100	75.3	100	31465.3	13461.3	73549.0
		PIII(D14)	13	13	100	75.3	100	79774.0	50733.0	125439.0
		PIII(D30)	13	13	100	75.3	100	71028.8	48687.2	103622.7
		PIII(D180)	13	13	100	75.3	100	27286.9	18489.9	40269.3
	HIV	PRE	14	0	0.0	0.0	23.2	62.5	62.5	62.5
		PREIII	14	9	64.3	35.1	87.2	198.4	99.0	397.7
		PIII(D7)	14	14	100	76.8	100	39928.9	21751.5	73297.1
		PIII(D14)	14	14	100	76.8	100	59932.0	37464.8	95872.6
		PIII(D30)	14	14	100	76.8	100	57653.6	35758.1	92956.1
		PIII(D180)	14	14	100	76.8	100	26520.6	14387.7	48885.0

PIII(D180) = Day 180 Post Dose 3

				≥42 mEL.U/mL				GMC(mEL.U/mL)		
						95% CI				95% CI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
HIV.F4Co Ab.IgG	HIV-CQ	PRE	13	0	0.0	0.0	24.7	21.0	21.0	21.0
		PREIII	13	13	100	75.3	100	217.8	147.1	322.3
		PIII(D7)	13	13	100	75.3	100	37905.7	16622.6	86438.8
		PIII(D14)	13	13	100	75.3	100	83863.4	56912.6	123576.8
		PIII(D30)	13	13	100	75.3	100	74791.3	50872.9	109955.1
		PIII(D180)	13	13	100	75.3	100	42847.4	28001.7	65563.8
	HIV	PRE	14	0	0.0	0.0	23.2	21.0	21.0	21.0
		PREIII	14	14	100	76.8	100	330.2	194.0	562.0
		PIII(D7)	14	14	100	76.8	100	39948.9	24778.8	64406.3
		PIII(D14)	14	14	100	76.8	100	63951.9	45830.2	89239.0
		PIII(D30)	14	14	100	76.8	100	65633.5	42838.2	100558.8
		PIII(D180)	14	14	100	76.8	100	40715.4	24865.2	66669.5

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE = Pre Dose 1 PREIII = Pre Dose 3, i.e. Pre-Booster Dose PIII(D7) = Day 7 Post Dose 3 PIII(D14) = Day 14 Post Dose 3 PIII(D30) = Day 30 Post Dose 3 PIII(D180) = Day 180 Post Dose 3		
Safety Results: Number (%) of subjects with unsolicited adverse events occurring until Day 29 post-vaccination (Total vaccinated cohort)		
Most frequent adverse events - On-Therapy (occurring within the 32-day (Day -2 to Day 29) post-chloroquine administration period for the HIV-CQ Group or within the 30-day (Days 0-29) post-vaccination period for the HIV Group	HIV-CQ Group N = 13	HIV Group N = 15
Subjects with any AE(s), n (%)	8 (61.5)	13 (86.7)
Subjects with grade 3 AE(s), n (%)	3 (23.1)	2 (13.3)
Subjects with related AE(s), n (%)	5 (38.5)	8 (53.3)
Chills	1 (7.7)	6 (40.0)
Myalgia	3 (23.1)	2 (13.3)
Influenza like illness	2 (15.4)	2 (13.3)
Headache	1 (7.7)	3 (20.0)
Gastroenteritis	1 (7.7)*	1 (6.7)
Lymphadenopathy	1 (7.7)	1 (6.7)
Diarrhoea	1 (7.7)	-
Rhinitis	1 (7.7)	1 (6.7)
Arthralgia	1 (7.7)	-
Hangover	-	1 (6.7)
Injection site haemorrhage	-	1 (6.7)
Injection site reaction	-	1 (6.7)
Malaise	-	1 (6.7)
Back pain	-	1 (6.7)
Musculoskeletal stiffness	-	1 (6.7)
Dizziness	-	1 (6.7)
Insomnia	-	1 (6.7)
Oropharyngeal pain	-	1 (6.7)
Pruritus generalised	-	1 (6.7)
* 1 subject in the HIV-CQ group reported gastroenteritis 1 day before vaccination - : Adverse event absent Grade 3= event that prevented normal activities Related= event assessed by the investigator as causally related to the study vaccination		
Safety Results: Number (%) of subjects with serious adverse events during the entire study period (Total vaccinated cohort)		
Serious adverse event, n (%) [n considered by the investigator to be related to study medication]		
All SAEs	HIV-CQ Group N = 13	HIV Group N = 15
Subjects with any SAE(s), n (%) [n assessed by investigator as related]	0 (0.0) [0]	0 (0.0) [0]
Fatal SAEs	HIV-CQ Group N=13	HIV Group N=15
Subjects with fatal sae(s), n (%) [n assessed by investigator as related]	0 (0.0) [0]	0 (0.0) [0]

Conclusion:

At Day 14, the number of CD8+ T cells responders identified with frequencies of CD 8+ T cells expressing at least one cytokine among IL-2, IFN- γ , TNF- α were 1 (7.7%) in the HIV-CQ Group and 3 (23.1%) in the HIV Group.

Within 7 day post-vaccination, pain was the most frequent solicited local symptom in both groups, reported by 13 (100%) subjects in the HIV-CQ Group and 14 (93.3%) subjects in the HIV Group.

Within the 30 day post-vaccination, at least one unsolicited AE was reported for 8 (61.5%) and 13 (86.7%) of the subjects in the HIV-CQ Group and in the HIV Group, respectively. No SAEs or AEs of specific interest were reported during the study period.

No clinically relevant changes from baseline in haematology or biochemistry parameters could be observed in any of the

groups at any of the time points.

Date updated: 29-April-2014